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Abstract: Glucocorticoids (GCs) represent a well-known class of lipophilic steroid hormones biosyn-
thesised, with a circadian rhythm, by the adrenal glands in humans and by the inter-renal tissue
in teleost fish (e.g., zebrafish). GCs play a key role in the regulation of numerous physiological
processes, including inflammation, glucose, lipid, protein metabolism and stress response. This
is achieved through binding to their cognate receptor, GR, which functions as a ligand-activated
transcription factor. Due to their potent anti-inflammatory and immune-suppressive action, synthetic
GCs are broadly used for treating pathological disorders that are very often linked to hypoxia (e.g.,
rheumatoid arthritis, inflammatory, allergic, infectious, and autoimmune diseases, among others)
as well as to prevent graft rejections and against immune system malignancies. However, due to
the presence of adverse effects and GC resistance their therapeutic benefits are limited in patients
chronically treated with steroids. For this reason, understanding how to fine-tune GR activity is
crucial in the search for novel therapeutic strategies aimed at reducing GC-related side effects and
effectively restoring homeostasis. Recent research has uncovered novel mechanisms that inhibit
GR function, thereby causing glucocorticoid resistance, and has produced some surprising new
findings. In this review we analyse these mechanisms and focus on the crosstalk between GR and
HIF signalling. Indeed, its comprehension may provide new routes to develop novel therapeutic
targets for effectively treating immune and inflammatory response and to simultaneously facilitate
the development of innovative GCs with a better benefits-risk ratio.
Keywords: glucocorticoid; glucocorticoid receptor; hypoxia inducible factor; crosstalk; immune
modulations; inflammation
1. Introduction
The name “glucocorticoid” (GC) is a portmanteau word (glucose + cortex + steroid),
which derives from their key role in the regulation of glucose metabolism, their biosynthesis
at the level of the adrenal cortex and their steroidal structure. They represent a well-known
class of lipophilic steroid hormones synthetized, with a circadian rhythm, by the adrenal
glands in humans and by the inter-renal tissue in teleost fish. GC circadian production
in mammals is tuned by the hypothalamus-pituitary-adrenal (HPA) axis, which is the
equivalent of the hypothalamus-pituitary-inter-renal (HPI) axis in teleost fish. Both are
essential for stress adaptation [1–4]. The axis consists of a highly conserved regulatory
system present in all living organisms aimed at maintaining a dynamic equilibrium in
the body in response to external and internal stimuli, which is fundamental to assure
homeostasis and survival. Cortisol, the end-product of the HPA/I axis, is the main GC
both in humans and teleost fish and plays a fundamental role in the maintenance of both
resting and stress-related responses [5–8].
Since their discovery in the 1940s [9], much has been learnt of GC molecular modes
of action [10–23]. In particular, the glucocorticoid receptor’s characterization as a DNA-
binding protein that regulates transcription initiation [24], the cloning of GR [25,26] and the
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breakthrough that most of the immunosuppressive actions of GCs occur via interfering with
key inflammatory transcriptional regulators such as NF-κB and AP-1 [27–30], represent the
main milestones.
Natural and synthetic glucocorticoids have been widely used for decades as effective
anti-inflammatory and immunosuppressive treatments to control pathological disorders,
which are very often linked to hypoxia. In particular, they have been broadly used to treat
both acute and chronic inflammations, including inflammatory bowel disease, rheumatoid
arthritis, multiple sclerosis, eczema and psoriasis, as well as being used in treatment of
various leukaemias and in immunosuppressive regimes upon organ transplant [31–36].
At any point in time, an estimated ~1% of the total adult UK population receives oral
glucocorticoid therapy [37]. However, due to the presence of adverse effects [38] and GC
resistance [39–42], their therapeutic benefits are limited in patients chronically treated with
these steroids. Examples of the most common GC-related side effects include osteoporosis,
glaucoma, diabetes, skin atrophy, abdominal obesity, dyslipidemia, hypertension in adults
and growth retardation in children [16,43,44].
Cortisol exerts its functions through direct binding to the glucocorticoid receptor (GR),
but also to the mineralocorticoid receptor (MR), which binds cortisol with even higher
affinity [45,46]. As transcription factors, both GR and MR compete for the same ligands,
can form heterodimers and homodimers with each other, recognize and bind many of the
same hormone response elements on the DNA, and share numerous coregulatory proteins
involved in the gene transcription initiation. Importantly, GCs activate MR in most tissues
at basal levels, whereas activate GR under stressful conditions or at the diurnal peak [47].
Once bound together, they form an active complex which can function in the nucleus
to modulate the transcription of effector proteins, as well as in the cytoplasm to hamper tar-
geted transcription factors activity. Historically, these functions have been coined genomic
and nongenomic modes of action, respectively [48–51]. Importantly, GCs and their kindred
intracellular receptors, represent critical checkpoints in the endocrine control of vertebrate
energy homeostasis. Indeed, if HPA axis activity is not accurately regulated, GC imbalance
may result in different pathological conditions such as hypertension, severe cardiovascu-
lar, immunological and metabolic complications (e.g., Addison’s disease (GC deficiency)
and Cushing’s syndrome (GC excess)) [52–54]. In addition, alterations or flaws in the
HPA axis response are tightly associated with a broad range of inflammatory and autoim-
mune diseases, both in humans and in animal models. The latter include Crohn’s disease,
rheumatoid arthritis, colitis, inflammatory bowel disease, multiple sclerosis (whose animal
equivalent is autoimmune encephalomyelitis), dermatitis, and asthma. Inflammatory con-
ditions include fibromyalgia, chronic fatigue syndrome, depression, and post-traumatic
stress disorder (PTSD) [55–61]. Moreover, even if the biological effects induced by GCs
are usually adaptive, their abnormal activity may contribute to a series of acute metabolic
diseases which include insulin resistance, obesity, and type 2 diabetes [62,63]. Thus, fur-
thering the research on how GCs precisely work and interact with other pathways may
provide better tools to treat these diseases and simultaneously allow the development of
selective GR agonists and specific drug-targeting strategies.
Similarly to GCs that are involved in numerous homeostatic maintenance activities
(e.g., metabolism of protein, carbohydrate and lipid, etc.) [64], the HIF signalling path-
way exerts a pivotal role in ensuring homeostasis, the preservation of which is essential
for the correct functioning of the cell. In this regard, the ability to perceive and quickly
respond to changes related to environmental oxygen availability is controlled by the
hypoxia-inducible factor transcription factors (HIF) family. Hypoxia is a common patho-
physiological occurrence, with a profound impact both on human and animal physiology,
in which oxygen availability to cells, tissues or to an organ is reduced below a certain
threshold (O2 levels < 2%) [65,66]. HIF transcription factors are key homeostatic regulators
which coordinate a metabolic shift from aerobic to anaerobic metabolism to assure cell
survival, both in mammals and in zebrafish [67–71].
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The HIF pathway is finely regulated by the PHD3-VHL-E3 ubiquitin ligase complex
the aim of which is to maintain low basal HIF levels that can rapidly increase to promptly
respond when oxygen levels decrease. This avoids any activation of the HIF pathway under
normoxic conditions. As a transcription factor, HIF drives the hypoxic response via binding
to specific hypoxia-response elements (HREs). These are involved in decreasing oxygen
consumption and increasing oxygen and nutrient delivery [72–74]. Interestingly, HIF
signalling can tune its own activation via negative feedback by inducing the expression of
the oxygen sensors proteins (PHDs), in particular prolyl hydroxylase 3 (PHD3) in zebrafish
and PHD2 in humans and mice [75,76].
However, although the HIF response is aimed at restoring tissue oxygenation and
perfusion, it may sometimes be maladaptive and may contribute to the onset of different
pathological conditions (e.g., inflammation, stroke, tissue ischemia and growth of solid
tumours) [65]. Thus, both glucocorticoids and hypoxia-induced transcriptional responses
have been shown to exert crucial roles in tissue homeostasis and in the regulation of cellular
responses to stress and inflammation [77–82].
Recent studies have also strengthened the knowledge on the important crosstalk
between these two major signalling pathways. To this purpose, the aim of the present
review is to discuss the evidence accumulated to date about such crosstalk. We also describe
novel mechanisms by which GR and HIF influence each other, both in vitro and in vivo,
and how these could be exploited to develop novel therapeutic targets required to overcome
GC-related and HIF-related diseases. To this end, the use of the zebrafish (Danio rerio) as
an effective in vivo model organism has become more and more important to study how
both hypoxic and glucocorticoid signalling function in vivo. Indeed, zebrafish share all the
components of the human HIF and GC pathway, and the zebrafish has been demonstrated
to be a very informative and genetically tractable organism for studying both hypoxia
and the stress response both in physiological and pathophysiological conditions [76,83–87].
Finally, the ease use of medium to high throughput drug screening [88] and genetic
tractability via the CRISPR/Cas9 based mutagenesis method [89–91] make the zebrafish
particularly suitable not only for genetic dissection of pathways themselves, but also
crosstalk between pathways studied at the level of whole organism.
2. Glucocorticoids
2.1. Biosynthesis, Secretion and Availability
GCs are essential steroid hormones biosynthesized and secreted by the adrenal
cortex/inter-renal gland both in a circadian manner and in response to stress. The lat-
ter is generally defined as a status of real or perceived threat to homeostasis. Assuring
homeostasis in the presence of stressors requires the activation of an intricate series of
coordinated biological responses performed by the nervous, endocrine and immune sys-
tems [62,92]. The key anatomical structures that regulate the stress response are located
both in the central nervous system and in peripheral tissues. The primary effectors of the
stress response are localized in the paraventricular nucleus (PVN) of the hypothalamus, in
the anterior lobe of the pituitary gland and at the level of the adrenal gland. These three
main structures are generally referred to as the hypothalamic-pituitary-adrenal (HPA) axis
in humans, and as the hypothalamic-pituitary-inter-renal axis (HPI) in zebrafish [62,92,93].
Among these, the hypothalamus is the initial stressor recognition site for both internal and
external signals. In mammals, neurons localized in the paraventricular nucleus synthe-
size both corticotropin-releasing factor (CRF) and arginine vasopressin (AVP), which are
released into hypophyseal portal vessels that access the anterior pituitary gland. On the
other hand, in teleosts, there is a direct neuronal connection to endocrine cells through
the hypophyseal stalk, since they lack a portal system between the hypothalamus and the
pituitary gland [94]. Here, CRF binding to its receptor localized on pituitary corticotropes
triggers the release of adrenocorticotropic hormone (ACTH) into the systemic circulation.
In humans, ACTH derives by post translational modification of its precursor encoded by
the proopiomelanocortin (POMC) gene. Of note, due to genome duplication, two pomc
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genes named pomca and pomcb have been identified in zebrafish [95–97]. However, only
pomca seems to be expressed in the pituitary gland and is required for the inter-renal organ
development [98,99]. The main target of ACTH is the adrenal cortex in humans and the
inter-renal tissue in teleosts, where it binds to the melanocortin 2 receptor (MC2R) on the
steroidogenic cells. Here, it stimulates cortisol biosynthesis and secretion starting from
cholesterol [62,92,100,101].
Finally, once released into the systemic circulation, GCs can access target tissues (e.g.,
liver, heart, and vascular tissues) to exert metabolic and cardiovascular effects and the brain
itself, in order to support cognitive processes required to tackle a threatening situation [102].
Under non stressful conditions, glucocorticoid levels in the serum are homeostatically
controlled by the HPA monitoring activity, whereas glucocorticoid availability is further
tuned at a tissue and cellular level. Circulating glucocorticoids are primarily bound to
corticosteroid binding globulin (CBG) and just a small percentage (5–15%) is bound to
albumin. As a result, the majority of GC is maintained in an inactive form, and only the
remaining 5% of systemic GC is free and bioactive. Hence, CBG concentration constitutes a
pivotal regulator of cortisol accessibility [103].
Importantly, GCs are also able to control their own biosynthesis and secretion by
tuning the activity of the HPA/I axis itself. This is particularly important to stop the stress
response and avoid an exacerbated reaction [104]. This is achieved via a GC-GR mediated
negative feedback loop, which acts both at the hypothalamic and anterior pituitary levels,
where GC-GR activity inhibits both CRH and POMC (ACTH precursor) biosynthesis and
release [2,21,23,105]. This occurs via a mechanism that requires GC-GR binding to an
nGRE within the pomca promoter [106]. For these reasons, pomca is a well-established
and frequently used readout of GR activity. In addition, GCs may indirectly control the
HPA axis activity through modulation of brain structures activity, such as the amygdala,
the hippocampus and the prefrontal cortex, that can, in turn, influence the activity of the
paraventricular nucleus [102,107–109].
2.2. The Glucocorticoid Receptor: Structure and Functions
GCs exert their systemic functions by binding to the glucocorticoid receptor (GR) and
the mineralocorticoid receptor (MR). Due to their lipophilic nature, GCs can passively
diffuse across the plasma membrane into the cytoplasm. Within the cells, their biological
availability is then regulated by two enzymes of the 11β-Hydroxysteroid dehydrogenase
(11β-HSD) family that work in an opposite fashion. 11β-HSD2 oxidizes cortisol into its
inactive form cortisone, reducing GC availability. Vice versa, 11β-HSD1 transforms cor-
tisone to cortisol, thereby increasing local GC activity. Inside the cell, GCs can bind to
their specific receptors GR and MR [33,102,110,111]. Both receptors, in the absence of their
ligands (unbound state) are associated in an inactive oligomeric complex with specific
regulatory proteins. Among these, heat shock protein-90 kD (HSP90), which binds both GR
and MR to the C-terminal domain, heat shock protein-70 kD (HSP70), p59 immunophilin,
Fkbp51 and Fkbp52 and the small p23 phosphoprotein maintain correct protein folding
of the receptor [102,112,113]. The GR, which belongs to the nuclear receptor transcription
factor family, is composed of different conserved structural domains [114]. These include
an N-terminal variable region (NTD) required for ligand-independent gene transactivation,
which contains a transactivation domain named activation function 1 (AF1). The latter
is responsible for the transcriptional activation and is involved in the association with
coregulators and the basal transcription machinery. A central DNA-binding domain com-
posed of two zinc fingers has been shown to be crucial both for GR homodimerization and
DNA-binding specificity. This is followed by an adjacent flexible hinge region allowing
proper DNA binding, dimerization, and nuclear translocation of the receptor [115]. Finally,
the C-terminal region (LBD) contains the ligand binding domain and a secondary transacti-
vation domain (AF2), regulated by hormone binding, which is essential for dimerization,
interaction with cochaperones, coregulators, and other transcription factors [116,117]. The
LBD also comprises a dimer interface which is fundamental for GR function and the
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binding of the heat shock protein 90 (Hsp 90) [118]. Both DBD and LBD include nuclear
localization signals, which are required for GR nuclear translocation. Finally, DBD also
incorporate the nuclear export signal sequence (NES) which targets it for export from the









Figure 1. Glucocorticoid receptor domain structure and translational isoforms. The N-terminal domain (NTD), which is
required for ligand-independent gene transactivation, includes a transcriptional activation function region (AF1). The latter,
which interacts with coregulators and with the basal transcriptional machinery, is the main posttranslational modifications
site. The LBD, which is made up of 12 α-helices and 4 β-sheets, forms a hydrophobic pocket needed for GC binding and
includes an AF2 domain. The latter allows interaction with coregulators in a ligand-dependent way. Finally, two nuclear
localization signals, named NL1 and NL2, are localized in the DBD-hinge region junction and within the LBD, respectively.
Asterisks indicate the location of the starting amino acid (aa position: 1, 27, 86, 90, 98, 316, 331, 336) of the eight different
GRα translational isoforms, which are characterised by progressively shorter NTDs.
Although the NTD is conserved, literature reviews and sequence alignments of human,
monkey, rat, and mouse GRs have revealed that there are another eight conserved AUG
start codons in the exon 2 (Figure 1). In humans, these were shown to produce various GR
isoforms with progressively shorter N-terminal transactivation domains [113]. These are
formed due to the presence of alternative Kozak translation initiation sequences which can
cause either ribosomal shunting or ribosomal leaky scanning mechanisms. This allows
the generation of different GR subtypes with truncated N-termini [119–123], which are
likely to be fully active. This is consistent with data from zebrafish, where a GR mutant
line (grsh551), characterized by a 1 bp deletion in the first coding exon (exon 2, Q48fsX3),
proved not to have any detectable phenotype [124]. This was confirmed further by ISH
analysis, which showed that both grsh551 mutants and wildtypes displayed an identical
downregulated pomca expression after synthetic GC (Betamethasone 17,21-dipropionate)
administration.
Synthetic GR agonists are supposed to trigger a potent GC response, which in turn
elicits the GC-GR mediated negative feedback loop, aimed to shut down their own biosyn-
thesis. As previously mentioned, this mainly occurs at the level of the pituitary gland via
downregulation of pomca [2,106,111]. For this reason, if GR is not functional, the GC-GR
negative feedback loop cannot occur and pomca expression should not be downregulated,
as occurs in grsh551 mutants. Indeed, in grsh551 mutants the feedback occurs normally.
In addition to alternative starts, alternative splicing at exon 9 is responsible for gen-
erating two different GR splice variants, namely GRα (777 aa) and GRβ (742 aa) [25,125].
These two receptor isoforms share an identical amino acid sequence between 1–727 aa and
then diverge. In particular, the human (h) GRα c C-terminal region contains 50 distinct
amino acid residues that form two alpha-helical structures that play a key ligand binding
role. In contrast, the hGRβ C-terminal is characterized by a shortened 15 non-homologous,
specific amino acid sequence that prevents GC binding [20,126,127]. Hence, hGRβ does
not bind traditional glucocorticoid agonists and lacks transactivational activity on GRE-
containing promoters, whereas hGRα is the canonical GR isoform. Nevertheless, hGRβ is
constitutively present in the nucleus where it has been shown to act as a dominant-negative
inhibitor of hGRα’s transactivational properties [127–129]. The mechanism behind this
inhibition is still uncertain, but several studies have suggested that competition between
both hGR isoforms for transcriptional coactivator proteins and/or the formation of inactive
GRα-GRβ heterodimers might be responsible for that [126,130–132].
Moreover, the function of hGRβ extends beyond antagonism of the hGRα isoform [133];
for instance, binding to the glucocorticoid antagonist mifepristone (RU486) has been also
reported [134,135]. In addition, it has been shown that increased hGRβ expression is
correlated both with the development of immune-related diseases (e.g., ulcerative colitis,
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leukemia and severe asthma) [136–138] and with glucocorticoid resistance in patients
affected by these diseases [139–141]. Interestingly, previous studies have established the
occurrence of a GR β-isoform in zebrafish larvae, which similarly to the hGRβ, confirmed
the lack of a role in transcriptional regulation and a dominant-negative inhibitor activity
on zGRα [19,20,142,143]. In this respect, zebrafish have been shown to be a reliable and
useful model system both for GC resistance and glucocorticoid receptor research [2,85].
2.3. GCs Mechanisms of Action
The conventional view of GC mechanism of action has been recently revised and
described as a more complicated multiprotein-regulated process. In this regard, it has
been shown that in both humans and zebrafish, upon cortisol binding, GR undergoes a
conformational change that involves an FKBP51-FKBP52 exchange. The latter triggers the
translocation of the GC-GR active complex into the nucleus. FKBP51 is a cochaperone pro-
tein that binds HSP90 and decreases the affinity of GR for cortisol. For this reason, FKBP51
has been considered an inhibitor of GR transcriptional activity and its overexpression has
been linked to GC resistance in autoimmune diseases [144–146]. After ligand binding,
FKBP51 is replaced by FKBP52, which in turn recruits dynein to support translocation of the
GC/GR complex to the nucleus [147,148]. This structural modification exposes the two GR
nuclear localisation signals, allowing the hormone-activated GR to dimerize with another
GC-GR molecule and to migrate into the nucleus via nuclear pores [149,150]. Interestingly,
this transcription factor complex can also act nongenomically (in the cytoplasm), where it
may interact via direct protein-protein interactions with other transcriptional regulators
and/or kinases (e.g., basal transcription machinery (BTM); phosphoinositide 3-kinase







Figure 2. Representative picture of the canonical GR signalling pathway. After binding to GC, GR undergoes a FKBP51-
FKBP52 mediated conformational change, becomes hyper-phosphorylated, dissociates from accessory proteins (chaperone
complex) and finally translocates into the nucleus. Here, after dimerization with other GRs, it regulates the transcription of
target genes by binding to DNA. Interestingly, GR may enhance or repress transcription of target genes by directly binding
to palindromic GC response elements (GRE), or by tethering itself to other transcription factors apart from DNA binding, or
in a composite manner by both directly binding GRE and interacting with transcription factors bound to neighbouring sites.
Created with BioRender.com.
Inside the cell nucleus, GC-GR complexes can directly bind to specific GREs, as
tetramers, to upregulate (transactivation) or downregulate (transrepression) the transcrip-
tion of target genes. Generally, the preferred GRE motif (AGAACAnnnTGTTCT in humans,
and GGAACAnnnTGTTCT in zebrafish) is an imperfect palindromic consensus sequence
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that consists of two 6 bp half sites. The three-nucleotide spacing in-between the two half
sites is essential for the GR to tetramerize on this sequence. Previous genome-wide studies
have shown that the same GRE can mediate both the GC-dependent induction of many
genes (positive GRE) and the repression of others (negative GRE) [113,154]. Interestingly,
the presence of specific inverted repeats negative GREs (IR nGRE), unrelated to simple
GREs has also been reported both in mice and in humans. These DNA binding sequences
are palindromic sequences consisting of two inverted repeated (IR) motifs separated by
1 bp. In particular, they bind GC-GR complexes to promote the assembly of cis-acting
GR-SMRT/NCoR repressing complexes [155,156] (Figure 2).
In summary, these findings indicate that the broadly different GC effects on various
tissues can be partially ascribed to cell type-specific differences in the chromatin landscape
that affects the accessibility of specific GREs for GR binding [157,158]. Furthermore, the GC
concentration at which the GR binds to GREs depends on the cell type and chromosomal
context. Another important feature of the GC-GR complex that makes its effects even more
versatile is that it can tune gene expression in different ways: by binding directly to DNA,
by tethering itself to other transcription factors bound to DNA, or via direct binding to
DNA and with neighbouring DNA-bound transcriptional regulators (composite manner,
Figure 2) [113,159,160].
2.4. The Mineralocorticoid Receptor: Structure and Functions
As previously mentioned, cortisol can bind not only to GR, but also to MR. Both are
members of the steroid receptor superfamily (corticosteroid receptors) of ligand-activated
transcription factors that enhance or repress the transcription of target genes, as well as
promote rapid nongenomic/extra-nuclear events via several cell signalling pathways [47].
The mineralocorticoid receptor is a 984-amino acid cytoplasmic protein that is characterized
by three different domains: an N-terminal transcriptional regulator domain, a DNA-
binding domain, and a ligand-binding domain responsible for the selectivity of hormone
binding. Analogously to GR, in its unliganded state MR is associated with a number of
chaperone proteins (HSP90, HSP70, FKBP51 and p23) that play a crucial role in trafficking
and maintaining MR in a suitable conformation for ligand binding [161].
MR has a ten-fold higher affinity for cortisol than GR and is preferably activated
under basal conditions, implying distinct roles for each receptor in the regulation of HPA
axis activity [162,163] It has also been observed that cortisol, even at lower concentra-
tions than those required to activate the GR, binds to MR and might enhance the activity
of several kinases (i.e., protein kinase C (PKC), cyclic adenosine 3′,5′-monophosphate
(cAMP), and phosphoinositide 3-kinases (PI3K)) involved in different signal transduction
cascades [4,47,164]. On the other hand, GR is primarily activated as a result of stress, or at
the diurnal peak when circulating cortisol levels are also peaking [162,165]. Cortisol also
exerts broad effects on mood and behaviour via MRs and GRs that are expressed in different
regions of the brain [166,167]. In particular, GR is widely expressed throughout the brain,
primarily in the PVN (stress-regulating centre) and in the prefrontal cortex-hippocampal-
amygdala circuitry (cognitive, emotional regulation and memory consolidation centre).
Vice versa, MR is predominantly expressed in the hippocampus, amygdala, and the lateral
septum (emotionality, social behaviour and feeding process hub) [168].
In mammals, the mineralocorticoid system is essential to regulate potassium and fluid
homeostasis upon aldosterone activation of MR. Even though cortisol is a high-affinity
ligand for MR, this steroid is deactivated in specific mineralocorticoid responsive tissues,
such as the kidney, by the previously mentioned 11b-HSD-2 enzymatic activity. This
allows aldosterone, a second corticosteroid present in mammals, to bind to this receptor.
Surprisingly, teleosts do not synthesize aldosterone, and cortisol has been shown to mediate
stress axis regulation, as well as the majority of the changes in iono-regulatory and osmo-
regulatory functions, via GR and MR signalling [1,4].
Interestingly, previous work performed both in rats and in teleosts showed that while
MR is involved both in basal and onset of stress-induced HPA/I axis activity, GR mainly
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controls its termination [4,169]. However, a recent zebrafish study highlighted that rapid
locomotor responses to quick changes in light illumination or water salinity (environmental
stressors) require GC-GR mediated HPI axis signalling, but not MR [170]. Finally, our
recently published research suggested that not only GR, but also MR signalling, is involved
in the GC-negative feedback regulation (HPI axis termination) and plays a key role in
assuring a proper HIF response in teleosts [171]. In view of this, furthering the precise role
of MR and mineralocorticoid modes of action in vivo, particularly in relation to in the HIF
signalling pathway, is warranted.
2.5. The Role of Glucocorticoids in Inflammation
Glucocorticoids suppress most of the events early in the inflammatory response and
subsequently facilitate inflammation resolution. They suppress both vasodilation and the
enhanced vascular permeability that occurs as a consequence of an inflammatory challenge,
and inhibit leukocyte migration from the inflamed region [10,172,173]. In addition, they
tune both distribution and trafficking of leukocytes, promote death/survival in some cells
and may affect cellular differentiation programmes [173–178]. It is well established that
many of the anti-inflammatory and immunosuppressive glucocorticoid actions are referable
either indirectly or directly to GC-GR mediated transcriptional regulation of numerous
genes expressed in leukocytes [173]. On the other hand, even though MR expression has
been reported in immune cells [179–181], its anti-inflammatory role has been considered
negligible so far [181,182], but rather surprisingly, MR-dependent proinflammatory effects
have also been noted [183,184]. It is presently unclear whether these effects are mediated
by the glucocorticoid cortisol or the mineralocorticoid aldosterone [185].
Glucocorticoids, through GR, can modulate gene expression in different ways [112,117].
Among these, transactivation is the mechanism by which GC predominantly induce the
transcription of numerous anti-inflammatory genes, such as GILZ, MKP-1 and IkBα. This
occurs through direct binding of single or multiple GC-GRs to palindromic glucocor-
ticoid response elements (GREs) [186–189]. Importantly, this mode of action has also
been shown to be responsible for several undesirable metabolic side effects linked to
chronic GC treatment [148]. On the other hand, transrepression is the mechanism by
which GC downregulate the transcription of inflammatory genes and requires direct
protein-protein interaction of GR to other transcription factors. This mode of action is
generally accepted to convey the beneficial GC anti-inflammatory effects, which are mainly
implicated in rapid cellular responses [40,148,190–192]. In particular, transrepression is
known to mainly occur via direct binding between the monomeric GC-GR complex and
transcription factors (e.g., AP-1, NF-kB, c-Jun, and c-Fos) activated by cytokines and
other pro-inflammatory stimuli, which synergistically coordinate the expression of several
proinflammatory genes [27,109,160,193–196]. Of note, most of these genes are commonly
overexpressed during chronic nonresolving inflammatory states. Interestingly, transrepres-
sion is not restricted to these transcription factors but also includes others such as CREB,
STAT, and T-bet [160,197]. As a result, the mutual antagonism between transcription factors
frequently impairs their transcriptional properties and prevents them from binding to their
corresponding DNA response elements.
As a consequence of the above considerations, optimal GC analogs should be char-
acterized by a high inhibitory activity against inflammatory mediators, coupled with a
low transactivation activity, in order to induce minimal side effects. Interestingly, different
steroidal and nonsteroidal ligands have been reported to have this dual function (e.g.,
RU-24858 and ZK-216348) [148,191,198–200]. These compounds have been reported to
suppress key inflammatory and immune transcription factor activity in vivo [198–202].
However, as stated before, since GCs can trigger gene expression via multiple routes,
unexpected secondary side effects might occur. For this reason, further research is also
warranted to elucidate the implications of the nongenomic GC-mediated activity both in
the immune and inflammatory scenario.
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Importantly, although the GC-GR complex is known for its anti-inflammatory effects,
the picture is more complex. Indeed, contrary to expectations, GR loss of function was
reported by Facchinello and coworkers to prevent the transcriptional activity linked to the
inflammatory immune response (i.e., of cytokines Il6, Il1β, Il8 and Mmp-13) [8], corrobo-
rating the hypothesis of a GC-GR mediated dual action on the immune system [35,203].
However, it is clear that further research is warranted to better elucidate this aspect. In
addition, GR was shown to synergistically induce proinflammatory genes by acting on
other signalling pathways [204–207]. Finally, studies also demonstrated that GCs increase
the transcription of numerous anti-inflammatory molecules such as interleukin-10 (IL-10),
interleukin-1 receptor antagonist (IL-1RA), secretory leukocyte inhibitory protein and
neutral endopeptidase [41,208].
Previous research also revealed that alterations in chromatin structure are important
for modulating the outcome of GC activity. Indeed, GR can interact differently with
histone acetyltransferases (HATs), with histone deacetylases (HDACs) and also kinases
(i.e., MSK1, PKA and JNK) [160]. These may, in turn, modulate the chromatin environment
by modifying chromatin accessibility and further tuning inflammatory and immune gene
expression [160]. Furthermore, since chromatin accessibility can predetermine GR binding
patterns and is crucial for cell-specific outcomes, it can provide novel molecular basis
for tissue selectivity [209,210]. In addition, another study showed that GR may directly
inhibit CREB binding protein (CBP)-associated HAT activity and may recruit HDAC2
to the p65-CBP HAT complex [211]. This novel glucocorticoid repression mechanism
suggests that histone acetylation inhibition represents an additional level of control of
inflammatory gene expression. Consequently, this further indicates that pharmacologically
manipulating specific histone acetylation status could be an alternative approach for
treating inflammatory diseases.
3. The HIF Signalling Pathway
The progression of the cell cycle is an energy-requiring process that demands a refined
metabolic regulation to occur. Indeed, it is well known that cells must overtake an energy
restriction checkpoint during G1 phase, in order to progress through the cell cycle. In this
regard, as practically all metazoan organisms require oxygen for metabolically converting
nutrients into energy, O2 represents a vital signalling molecule directing cellular functioning
and survival. Consequently, assuring oxygen homeostasis is a critical task that must
be precisely managed by cells in order to perform correctly and survive in a hostile
environment [212].
In vertebrate cells, this is primarily carried out by Hypoxia-Inducible Factors (HIFs),
which are a family of transcription factors that react both to environmental oxygen and
cellular energy alterations (e.g., hypoxia) [213]. HIFs are obligate heterodimers consisting
of three main α-subunits (HIF1α, HIF2α and HIF3α) and two constitutively stable aryl
hydrocarbon receptor nuclear translocators or β-subunits (ARNT1 and ARNT2). Both
HIF alpha and beta subunits are expressed in the cytoplasm and are basic helix-loop-
helix (bHLH)/Per-Arnt-Sim (PAS) transcription factors containing transactivation domains
(TADs) [214]. In particular, the initial bHLH domain, required for DNA binding, is followed
by a Per-Arnt-Sim (PAS) domain that acts as a molecular sensor. The latter is followed by
an oxygen-dependent degradation domain (ODD), which is targeted and hydroxylated
by the VHL-E3-ubiquitin ligase complex, and by an N- and C-terminal transactivation
domains (TAD-N and TAD-C). The latter is present in all the HIF-α subunits except for
HIF-3α, which only has the TAD-N activation domain. On the other hand, HIF-β/ARNT
being not targeted and degraded by the pVHL-E3 ligase complex lacks both the ODD and
the TAD-N domains, and has a constitutively active N-terminal nuclear localization signal
(NLS) [215,216] (Figure 3A).













Figure 3. HIF-α isoforms and their receptor HIF-1 /ARNT structural domains. (A) In vertebrates
both HIF-1α and HIF-2α, but not HIF-3α, contain a basic helix-loop-helix (bHLH) domain, a Per-Arnt-
Sim domain (PAS), an oxygen dependent degradation (ODD) domain, an N-terminal transactivation
domain (N-TAD) located in the ODD and a C-TAD localized in the C-terminal region. (B) The HIF
signalling pathway. Under normoxic conditions, PHDs hydroxylate HIF-α subunits on two specific
prolyl residues within the ODDD. In turn, VHL recognizes and binds to hydroxylated HIF-α and
then recruits the other components of the E3-ubiquitin ligase complex. The latter promotes the
ubiquitin-mediated proteasomal degradation of HIF-α subunits. Conversely, hypoxic conditions
inhibit PHD activity, and the subsequent degradation of HIF-α, which can, in turn, be stabilized in the
cytoplasm, can dimerize with HIF-β-subunit and migrate into the nucleus. Here, the HIF-αβ active
complex enhance the expression of target genes such as PHD3, VEGF, GLUT1 and EPO involved in
restoring oxygen homeostasis. Created with BioRender.com.
As previously mentioned, HIF-α subunits are characterized by a very fast turnover that
is post-translationally regulated by the PHD3-VHL-E3-ubiquitin ligase protein degradation
complex. Under normoxic conditions (normal oxygen levels), a set of prolyl hydroxylases
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(PHD1, 2 and 3) directly exploit the available molecular oxygen to hydroxylate two prolyl
residues (Pro402, Pro564) within the oxygen-dependent degradation domain (ODDD) of
the HIF-α subunits (Figure 3A). Then, the hydroxylated HIF-α isoforms are recognized and
targeted by the Von Hippel Lindau protein (pVHL), which acts as the substrate recognition
component of the E3-ubiquitin ligase complex. The latter is characterized by a multiprotein
complex which consists of Elongin B, Elongin C, Ringbox 1 and Cullin 2 [217]. Once this
complex ubiquitinates the HIF-α subunits, it directs them towards proteasomal degradation
to avoid an aberrant stabilization and activation of the HIF pathway when it is not necessary
(Figure 3B, normoxia). In addition, HIF-α may be hydroxylated by factor-inhibiting HIF
(FIH) on asparagine 803 (N803), which prevents the recruitment of the transcriptional
coactivator p300/CREB-binding protein (p300/CBP) and reduces the effectiveness of HIF
transcriptional activation [218].
Another level of complexity in the regulation of HIF response is represented by the fact
that both FIH and PHDs are dioxygenases requiring O2, ferrous iron (Fe
2+), 2-oxoglutarate
and ascorbate, as cosubstrates, to hydroxylate HIF-α [219]. The ferrous iron is an essential
cofactor for the enzyme to be assembled into its active conformation, as prolyl hydroxylases
contain Fe2+ in their hydrophobic active centre. Moreover, the O2-binding event requires
ascorbate to maintain this iron molecule into its ferrous state, whereas the transferring
of one oxygen atom to 2-oxoglutarate (2-OG) is required to hydroxylate HIF-α subunit.
This reaction yields both succinate and carbon dioxide as reaction products, making this
catalytic process irreversible. During a complete reaction, Fe2+ is transiently oxidized to
Fe4+ and then reduced to the Fe2+ state. Interestingly, when α-ketoglutarate is converted
into succinate without hydroxylation of a peptide substrate, Fe2+ is oxidized to Fe3+. In
this process, ascorbate is also necessary to reduce Fe3+ back to Fe2+ to allow the enzyme
to be recycled [220]. Finally, mitochondrial reactive oxygen species (ROS), may also affect
hydroxylase activity by post-translationally modifying these enzymes by oxidizing their
cysteine residues, and/or by attacking ferrous iron (Fe2+) [221,222].
By contrast, the presence of reduced O2 levels impairs both PHD and FIH enzymatic
activity and leads to HIF-α stabilization. Therefore, pVHL is no longer able to recognize
and target HIF-α to proteasomal degradation when the latter is not hydroxylated. This
allows HIF-α and β subunit heterodimer formation, followed by ARNT-mediated translo-
cation in the nucleus. Here, p300/CBP may interact with the HIF-αβ transcription complex
to further activate the hypoxic response. This implies the upregulation of target genes
that are involved in decreasing oxygen consumption and increasing oxygen and nutrient
delivery [31]. This occurs via direct recognition and binding of HIF to hypoxia-response
elements (HREs). The latter are characterized by the presence of a consensus sequence
G/ACGTG located within the promoter regions of target genes, such as phosphofructok-
inase, adrenomedullin, erythropoietin and vascular endothelial growth factor [73,74,78]
(Figure 3B, hypoxia).
The Role of Hypoxia in Inflammation
Hypoxia and inflammation share an intimate relationship. Both in cells and tissues the
hypoxic response plays a vital role in the metabolic changes that control cellular adaptation
to low oxygen availability. In a hypoxic scenario, HIF exerts a proinflammatory role by
stimulating multiple aspects of the host immune system, from enhancing the phagocyte
microbicidal capacity, to driving T-cell differentiation and cytotoxic activity [223,224]. The
HIF-mediated activation of the inflammatory response is a complex process, which is
characterized by the simultaneous activation of both pathways in several pathological
circumstances such as chronic inflammation, wound healing and solid tumours [225].
Hypoxia is able to activate monocytes, macrophages and dendritic cells by tuning their gene
expression and cytokine secretion [226–229]. In addition, it triggers NF-κβ stabilisation,
which acts as a master regulator of the inflammatory and anti-apoptotic response. This is
achieved, as for HIF-α, via the oxygen dependent inhibition of prolyl hydroxylase activity.
Then, this triggers the decrease in IκB kinase beta (IKKβ) hydroxylation, which leads to the
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activation of NF-κβ [87,230–232]. In turn, in response to hypoxia, LPS, or bacterial infection,
NF-κB has been demonstrated to directly increase HIF-1α transcription [233–235]. This
allows further confirmation of the extensive crosstalk between these two major molecular
players involved in inflammation and hypoxia [236]. This interaction has been well studied
in a zebrafish model of wound healing, where HIF-1α pathway activation was observed
to delay neutrophil resolution [82]. This is believed to occur as a consequence of HIF
activation inside the neutrophils themselves, and seems to be related to an augmented
neutrophil apoptosis rate coupled with decreased trafficking away from the comorbid
site [237].
Interestingly, several studies have also reported the presence of an interplay be-
tween hypoxia and glucocorticoid-dependent signalling pathways. Indeed, glucocorticoids
have been observed via in vitro studies both to enhance and inhibit HIF pathway acti-
vation [77–81]. Analogously, hypoxia has been shown to attenuate the glucocorticoid
anti-inflammatory response and to elicit corticosteroid insensitive inflammation [238–240].
In this regard, it is important to note that despite hypoxia being considered pro-
inflammatory, HIF can also positively interact with pathways with apparently opposite
effects. For instance, it was shown that HIF and GC signalling converge at the level of
the promoter region of inflammatory factors to reciprocally tune their expression in a
T-lymphocyte cell line model [241]. In relation to inflammation regulation, particular
attention should be also placed on GILZ [242], which is an important mediator of the GC
anti-inflammatory and immune-suppressive activity. Indeed, GILZ overexpression in T-
cells has been demonstrated to suppress NF-κB activation by binding to its p65 subunit and
preventing its nuclear translocation [243,244]. Moreover, it has been reported that hypoxia
can strongly upregulate GILZ expression in rat macrophages, and that pretreatment with
synthetic GC (Dexamethasone) amplifies these effects [242]. Additionally, in vitro studies
revealed that under hypoxic conditions GILZ inhibition led to increased transcription and
protein secretion both of proinflammatory mediators IL-1 and IL-6 and abolished the GC
inhibitory effect on their expression. These findings indicate that GILZ plays a key role in
tuning adaptive responses to hypoxic conditions by inhibiting pro-inflammatory responses
and by mediating the GC anti-inflammatory responses [242].
Macrophages, which are broadly classified as M1 (pro-inflammatory), or M2 (anti-
inflammatory) are a class of immune cells, residing in all tissues, that play a crucial role
during inflammation [245]. In addition to their protective immunological function they
also stimulate growth factors and pro-angiogenic cytokine expression such as basic fi-
broblast growth factor (FGF-2) and vascular endothelial growth factor (VEGF-A), thereby
triggering angiogenesis [246]. Interestingly, under hypoxic conditions, HIF can also pro-
mote their polarization towards the M2 phenotype in order to modify the inflammatory
microenvironment by decreasing the release of proinflammatory cytokines [247].
Conversely, GCs, being angiostatic, are often exploited to treat angiogenesis-related
diseases, including solid tumours. In particular, GCs control angiogenesis by inhibiting
proliferation, migration and sprouting of endothelial cells, and by decreasing both cytokines
and pro-angiogenic factor expression [248]. Consequently, since both hypoxia and GC are
specifically involved in inflammation, where they tune angiogenesis and affect macrophage
function (i.e., by upregulating GILZ expression), understanding how precisely this interplay
occurs in vivo, may have a wide physiological significance in health and disease, and may
help researchers to develop more effective anti-inflammatory drugs in the future.
4. HIF-GC-Crosstalk: Previous Insights
Modulating the HIF pathway has the potential to be clinically exploited as thera-
peutic treatment for a variety of pathological conditions which include stroke, ischemia,
spinal cord injury, inflammation, cancer, wounding, chronic anaemia and bone
regeneration [99,224,249–252]. To this end, an unbiased chemical screen performed in
our laboratory on zebrafish larvae discovered that HIF associated transcriptional responses
are potently activated by GCs, particularly in the zebrafish liver [253].
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Moreover, by translating these observations to human tissues, it has been possible
to show that GCs promote HIF stabilization, without the need of the GR DNA binding
domain (non-genomic action), in primary human hepatocytes and intact liver slices. In this
regard, since c-src inhibitor PP2 treatment was able to rescue this effect, this suggested a
role for GCs in promoting c-src–mediated proteasomal degradation of pVHL followed by
stabilization of HIF-α subunit [253]. According to these data, since the liver is an important
regulator of blood glucose levels, and both GC and HIF promote gluconeogenesis and
glycogen storage in the liver, the crosstalk between these may contribute to GC effects on
glucose metabolism and may have a wider physiological significance in health and disease
than previously expected.
Indeed, both GCs and hypoxic transcriptional responses are mutually involved in
assuring tissue homeostasis by controlling cellular responses to various forms of stress and
inflammation, especially affecting glucose metabolism.
Synthetic GCs have been widely used for years as anti-inflammatory drugs for treat-
ing pathological conditions in which hypoxia plays a role in disease progression, such as
rheumatoid arthritis and chronic obstructive pulmonary disease [31,32,35]. In humans, the
adaptive GC release in response to atmospheric hypoxia has been shown to be linked to
acclimatisation to high altitude, and the prophylactic treatment with GC has been broadly
exploited to mitigate the related mountain sickness [254]. Additionally, GC administra-
tion protects different organs from ischemic injury, as was observed especially against
experimental cerebral and hepatic ischemic/reperfusion injury [255–258].
The presence of an interplay between hypoxia and GC-dependent signalling pathways
has been previously reported in different in vitro studies [78–80,259]. However, these
studies reported conflicting results on the crosstalk between GC action and hypoxia, where
the latter limits GR-mediated transactivation both in pulmonary endothelial and hepatic
epithelial cells [78,80]. The first data about the interaction between HIF and GR were
presented by Kodama et al., 2003 [79]. By exploiting an artificial approach using Gal4-
fusion reporter assays, they found that the ligand-dependent activation of GR increases
hypoxia-dependent gene expression and hypoxia response element (HRE) activity in
HeLa cells.
Moreover, using dexamethasone-treated COS7 cells co-transfected with expression
plasmids for either GR or GAL4-LBD and GFP-HIF-1α and exposed to hypoxic conditions,
they showed colocalization of the GR and HIF-1α in the nucleus. For this reason, Kodama
and colleagues postulated the presence of a direct protein-protein interaction between the
GR LBD and HIF-1α as the main mechanism for GC-dependent enhancement of the HIF
pathway but failed to demonstrate it via GST pulldown assays.
Leonard et al., 2005 [78], subsequently confirmed via microarray analysis that GR
is upregulated (from 7-fold to 12-fold) by hypoxia over time (0–36 h) in human renal
proximal tubular epithelial cells. Furthermore, using a cell-based GRE luciferase reporter
system, they showed that hypoxic exposure can potentiate dexamethasone-stimulated GRE
promoter-reporter activity.
Using ACTH secreting mouse pituitary tumor AtT-20 cells, Zhang et al., 2015 [259]
demonstrated that GR expression levels were enhanced by HIF-1α under hypoxic condi-
tions. However, dexamethasone treatment was able to cause the downregulation of GR
expression in a HIF-1α dependent way. Finally, even if this was confirmed by transfecting
AtT-20 cells with HIF-1α siRNA and culturing them under normoxia or hypoxic condi-
tions, the involved underlying mechanism remains unclear. Unfortunately, the impact on
downstream GR/GC pathway activity was not assessed.
By contrast, a dexamethasone-related inhibition of HIF-1α target gene expression in
hypoxic HEPG2 cells was revealed by Wagner et al., 2008 [80]. In particular, via Western
blot analysis they showed that dexamethasone reduces nuclear HIF-1α protein, as the
HIF-1α amount was higher in cytosolic cell extracts than in the nuclear extracts upon DEX
treatment. This cytoplasmic retention of HIF-1α suggested a blockage of nuclear import,
via a still unknown mechanism, which resulted in a reduced HIF target gene expression.
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In addition, by exploiting a luciferase assay the author revealed that dexamethasone at-
tenuates HIF-1 activity not only in a GR- dependent way but this effect depends on the
presence of functional HREs. Importantly, Wagner et al. attributed these contradicting
results (compared to Kodama’s) to the fact that they conducted all their cell-culture experi-
ments in the presence of fetal bovine serum (FBS), avoiding not only growth and cell-cycle
arrest, but also the synchronization of the cells. This might be an important issue, as many
cellular processes depends on the cell cycle phase.
In the following years, Gaber et al., 2011 [260] investigated the interaction between
macrophage migration inhibitory factor (MIF), HIF and the effect of GCs in human primary
nontumor CD4+ Th cells and Jurkat T cells. In contrast to the previous observations, this
study showed the presence of a clear dexamethasone-dose dependent inhibition of HIF-1α
protein expression, which resulted in decreased HIF-1 target gene expression. Therefore,
as an alternative to the Wagner et al. 2008 hypothesis, they proposed a model based
either on rapid DEX-mediated induction of HIF-1α inhibitors (e.g., PHD1–3, FIH, and
pVHL) or fast DEX-mediated suppression of hypoxia-induced signalling. Cumulatively,
these contradicting in vitro data reflect the diversity present among the cell types that
were used in these studies and the different mechanisms by which these were conducted.
Methods that are less cell line and cell culture-dependent would be helpful to understand
the interaction better, and in vivo analysis would be valuable, in this respect.
5. HIF-GC-Crosstalk: HIF as Negative Regulator of GC Biosynthesis
and Responsiveness
Zebrafish have been demonstrated to be informative organisms in which genetic
mutations and chemical modulators of HIF and GC signalling pathways can be easily
combined, not only in physiological, but also in pathophysiological conditions. Using
such approaches [89,91,261,262], we demonstrated that the upregulation of HIF signalling
repressed both GR responsiveness and cortisol levels, whereas GCs enhanced HIF activity.
The latter effect was mediated both by the GR and MR receptors, and we speculated that
GC can promote HIF-1 signalling via multiple routes [171].
With respect to the effect of HIF signalling on GC responsiveness, it was particularly
interesting to note that a strong activation of HIF signalling can blunt GR transcriptional
regulation, whereas reduction of HIF signalling via arnt1 loss of function is able to derepress
it. Interestingly, HIF activity leads to a repression of GC biosynthetic genes, which is
unusual since HIF is generally considered to be a transcriptional activator. However, the
precise molecular mechanism behind this the strong negative HIF-mediated action remains
to be resolved.
As stated before, GCs control a plethora of physiological processes, act on almost all
the tissues and organs in the body and have a strong anti-inflammatory and immunosup-
pressive actions. For this reason, their production must be finely controlled by the HPA/I
axis [113]. If the latter is disrupted by factors such as chronic stress, disease progression
and prolonged exogenous GC treatment, a tissue-specific decrease in GRα functional pool
coupled with an uncontrolled GC biosynthesis may result in the development of acquired
GC resistance. This results in both excessive inflammation and HPA axis hyperactivity,
which are known to contribute to the progression of numerous psychological and patho-
logical conditions (e.g., cardiovascular disease, depression, schizophrenia, diabetes, and
cancer, among others) [263,264].
Cumulatively, the presence of high cortisol levels coupled to a significant decrease in
GC sensitivity are seen as a hallmark of glucocorticoid resistance (e.g., in the gr mutant
fish). Therefore, it is rare that a GC-resistant condition coincides with low cortisol levels.
In addition, many studies have shown that if GC levels drop, pomca is upregulated to
compensate for the reduced GC levels and feedback [2,87]. However, in the presence of
upregulated HIF pathway (in vhl mutant fish), an unusual situation is seen where pomca is
not upregulated, although GR-responsiveness is strongly attenuated, and GC levels are
very low. Consequently, we speculate that HIF signalling can act as a second upstream
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controller of the GC-mediated stress response (in addition to cortisol levels themselves)
(Figure 4).
κ
Figure 4. Speculative scheme of how putative HIF-GC crosstalk occurs in the zebrafish. Previous
research highlighted that GCs may enhance both GR and MR-mediated responsiveness and stimulate
the HIF signalling. Conversely, upregulated HIF levels may inhibit GC biosynthesis by negatively
regulating pomca at the level of the pituitary gland. Consequently, this is believed to occur as a
logic homeostatic response exerted by HIF signalling to control not only its own activity but that of
glucocorticoids to facilitate inflammation resolution and homeostasis. Created with BioRender.com.
Indeed, since previous work in our laboratory highlighted that GCs may also act
as HIF activators [76,253] we inferred that HIF may, in turn, control cortisol levels by
acting on pomca expression. This would allow HIF signalling not only to manage its
own activity, but also to assure both stress resolution and homeostasis. The reason for
hypothesising that HIF signalling would counteract anti-inflammatory GC activity resides
in the fact that the simultaneous expression of both the upregulated HIF and GC pathways
would be detrimental to homeostasis. This is because HIF is a master regulator of cellular
pro-inflammatory responses to hypoxia, whereas GCs have a potent anti-inflammatory
and immune suppressive activity [171]. In this regard, it is interesting to note that our
proposed model effectively applies to the immune response context. Indeed, during
inflammation, we speculate that the crosstalk between GC and HIF may influence the
expression of downstream inflammatory effectors (e.g., GILZ and NF-κB) to eventually
assure homeostasis (Figure 5).
This hypothesis is in accordance with a previous report showing that hypoxia expo-
sure resulted in the downregulation of steroidogenic genes (StAR, cyp19b, cyp19a, cyp11c1,
hsd17b2 and hmgcr) in 72 hpf larvae, whilst zHIF-α loss of function stimulated the upreg-
ulation specifically of StAR, cyp11b2 and cyp17a1 [265]. Importantly, the fact that cortisol
levels were reduced in vhl-/- and upregulated in arnt1-/- is consistent with our assump-
tion. More speculatively, the fact that in teleosts GC biosynthesis is finely regulated by
hypothalamus-pituitary gland activity in a circadian way, and multiple studies have shown
an evolutionary connection between HIF signalling and circadian rhythms [266–269], sug-
gest that the interaction between GC and HIF may be tight and ancient.
Importantly, recent work from Watts et al., 2021 confirmed the role of HIF1α as a
direct regulator of steroidogenesis in the adrenal gland. Indeed, mice deficient in HIF1α in
adrenocortical cells exhibited both increased levels of steroidogenic enzymes, such as Star,
Cyp11a1, Cyp21a1 and Cyp11b1, and an enhancement in circulatory steroid levels. These
changes also resulted in cytokine alterations and modifications of the profile of circulatory
mature hematopoietic cells. However, additional mechanisms are possible and indeed
likely, one example being via miRNA103/107 [270]. Vice versa, HIF1α overexpression in-
duced the opposite phenotype characterized by strongly downregulated steroid production
as a result of impaired transcription of steroidogenic enzymes [271]. Therefore, the data
derived from zebrafish research are in accordance with mice studies. As a consequence of
the above considerations, the HIF-mediated pomca negative regulation seems to be a logic
homeostatic response. Moreover, with respect to the stimulating effects of GCs on HIF
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signalling, it is important to point out that in vivo genetic analysis showed that functional
GR is an essential prerequisite for high HIF signalling levels. Unfortunately, a molecular
explanation for this is still elusive, and research towards this direction (e.g., ChIP seq,
pull-down assay) is warranted.
κ
Figure 5. Speculative scheme of how the putative HIF-GC crosstalk occurs in inflammation. We
speculate that HIF can negatively regulate pomca expression to control not only its own activity but
also that of glucocorticoids throughout the inflammatory process. Indeed, if not properly controlled,
glucocorticoids could upregulate GILZ, whose overexpression has been demonstrated to suppress
NF-κB activation. Since the latter can, in turn, increase the transcription of HIF-1α in response to
hypoxic and inflammatory stimuli, its downregulation would hamper HIF activation and avoid
essential pro-inflammatory HIF-mediated effects to occur.
Finally, the importance of GCs in the HIF pathway was further analysed by studying
MR contribution to HIF signalling itself. Our data showed that in addition to the glu-
cocorticoid receptor, the mineralocorticoid receptor acts partially redundantly to allow
HIF signalling in the zebrafish. This hypothesis is consistent with work from Faught and
Vijayan [4] showing that both Gr and Mr signalling are involved in the regulation of the
GC negative feedback. It is also consistent with the finding from Rybnikova et al., that both
GR and MR are involved in brain hypoxic tolerance induction [272]. If these results hold
up in mammals, this suggests GR and MR inhibitors may be usable to reduce excessive
HIF activity in certain situations; for instance, in vhl deficient tumours.
In addition, dexamethasone (GC agonist) has been recently shown to decrease short-
term mortality and to reduce the need for mechanical ventilation in hospitalised patients
with COVID-19 [273,274]. Since the latter show low blood oxygen saturation, and HIF
is very likely to be overactivated in them, could it be that they have either too low GC
levels or GR responsiveness? Since synthetic GC administration rescues these patients with
upregulated HIF, is there a functional link between these two facts? Is this related to what
we have seen in the zebrafish?
Future work that could be brought to any potential drug development would include
additional preclinical testing both in vitro and in vivo, aiming to better elucidate how HIF-
GC interaction take places at molecular level. Cumulatively, understanding the molecular
mechanisms behind the HIF-GR crosstalk and their target gene activation is of undeniable
importance and deserves significant research investment in the near future.
6. Conclusions and Future Directions
The development of novel therapeutic targets and of innovative GCs with a better
benefits-risk ratio is of indisputable relevance to effectively treating immune and inflam-
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matory responses. In this regard, the zebrafish has been shown to be an effective model
organism that can be used for investigating not only the molecular mechanism behind
glucocorticoid receptor modes of action, but also in drug discovery studies. To this end, it
is important to define efficient readouts for both desired and undesired effects of GC.
In the last decades few in vitro studies have highlighted the potential for crosstalk
between the hypoxia-inducible factor and glucocorticoid transcriptional responses. How-
ever, how this interplay takes place precisely in vivo has only been recently proposed,
and use of the zebrafish as a model organism has shown that HIF can repress not only
cortisol biosynthesis, but also GR responsiveness to synthetic GC. Conversely, research has
uncovered the importance of the GC pathway in driving HIF signalling and highlighted
a novel mineralocorticoid receptor contribution to the HIF-GC crosstalk. In addition, the
interaction between HIF-GC and NF-kB signalling might be of high relevance. Indeed,
investigating the putative mechanisms behind adaptation to severe hypoxia might help
to unravel the hypoxia-related causes and effects in acute inflammatory disease. Finally
understanding how MR precisely impacts on HIF signalling might be extremely important
to provide a potential additional avenue to downregulate the HIF pathway in vivo, as it has
been proven difficult to do so in the tumour microenvironment. Overall, new insights into
the interaction between HIF and GR, both in vitro and in vivo, are promising directions for
future research and might inspire new therapeutic approaches.
Author Contributions: Conceptualization, D.M. and F.J.M.v.E.; writing—original draft preparation,
D.M.; writing—review and editing, D.M. and F.J.M.v.E.; visualization, D.M. and F.J.M.v.E. All authors
have read and agreed to the published version of the manuscript.
Funding: DM was awarded by a University of Sheffield, Biomedical Science department studentship
and supported by two BBRSC grants to FVE (BB/R015457/1; BB/M02332X/1). FVE was funded
by two Biotechnology and Biological Sciences Research Council (BBRSC: https://bbsrc.ukri.org/
(accessed on 2 December 2021)) grants (code 1: BB/R015457/1; code 2: BB/M02332X/1). The funders
had no role in study design, data collection and analysis, decision to publish, or preparation of
the manuscript.
Institutional Review Board Statement: Not applicable.
Informed Consent Statement: Not applicable.
Data Availability Statement: Not applicable.
Conflicts of Interest: Authors report no conflict of interest.
References
1. Alsop, D.; Vijayan, M. The zebrafish stress axis: Molecular fallout from the teleost-specific genome duplication event. Gen. Comp.
Endocrinol. 2009, 161, 62–66. [CrossRef] [PubMed]
2. Griffiths, B.B.; Schoonheim, P.J.; Ziv, L.; Voelker, L.; Baier, H.; Gahtan, E. A zebrafish model of glucocorticoid resistance shows
serotonergic modulation of the stress response. Front. Behav. Neurosci. 2012, 6, 68. [CrossRef]
3. Tokarz, J.; Möller, G.; de Angelis, M.H.; Adamski, J. Zebrafish and steroids: What do we know and what do we need to know?
J. Steroid Biochem. Mol. Biol. 2013, 137, 165–173. [CrossRef]
4. Faught, E.; Vijayan, M.M. The mineralocorticoid receptor is essential for stress axis regulation in zebrafish larvae. Sci. Rep. 2018,
8, 18081. [CrossRef] [PubMed]
5. Munck, A.; Guyre, P.M.; Holbrook, N.J. Physiological Functions of Glucocorticoids in Stress and Their Relation to Pharmacological
Actions. Endocr. Rev. 1984, 5, 25–44. [CrossRef]
6. Macfarlane, D.P.; Forbes, S.; Walker, B.R. Glucocorticoids and fatty acid metabolism in humans: Fuelling fat redistribution in the
metabolic syndrome. J. Endocrinol. 2008, 197, 189–204. [CrossRef]
7. Kuo, T.; McQueen, A.; Chen, T.-C.; Wang, J.-C. Regulation of Glucose Homeostasis by Glucocorticoids. In Glucocorticoid Signaling:
From Molecules to Mice to Man; Wang, J.-C., Harris, C., Eds.; Springer: New York, NY, USA, 2015; pp. 99–126. [CrossRef]
8. Facchinello, N.; Skobo, T.; Meneghetti, G.; Colletti, E.; Dinarello, A.; Tiso, N.; Costa, R.; Gioacchini, G.; Carnevali, O.; Argenton, F.;
et al. nr3c1 null mutant zebrafish are viable and reveal DNA-binding-independent activities of the glucocorticoid receptor. Sci.
Rep. 2017, 7, 4371. [CrossRef]
9. Hench, P.S.; Kendall, E.C.; Slocumb, C.H.; Polley, H.F. The effect of a hormone of the adrenal cortex (17-hydroxy-11-
dehydrocorticosterone: Compound E) and of pituitary Adrenocortical Hormone in Arthritis: Preliminary Report. Ann. Rheum.
Dis. 1949, 8, 97–104. [CrossRef]
Cells 2021, 10, 3441 18 of 27
10. Perretti, M.; Ahluwalia, A. The microcirculation and inflammation: Site of action for glucocorticoids. Microcirculation 2000,
7, 147–161. [CrossRef] [PubMed]
11. Smoak, K.A.; Cidlowski, J.A. Mechanisms of glucocorticoid receptor signaling during inflammation. Mech. Ageing Dev. 2004,
125, 697–706. [CrossRef]
12. Newton, R.; Holden, N. Separating Transrepression and Transactivation: A Distressing Divorce for the Glucocorticoid Receptor?
Mol. Pharmacol. 2007, 72, 799–809. [CrossRef]
13. Necela, B.M.; Cidlowski, J.A. Crystallization of the human glucocorticoid receptor ligand binding domain: A step towards
selective glucocorticoids. Trends Pharmacol. Sci. 2003, 24, 58–61. [CrossRef]
14. Rhen, T.; Cidlowski, J. Antiinflammatory Action of Glucocorticoids—New Mechanisms for Old Drugs. N. Engl. J. Med. 2005,
353, 1711–1723. [CrossRef]
15. Yeager, M.P.; Guyre, P.M.; Munck, A.U. Glucocorticoid regulation of the inflammatory response to injury. Acta Anaesthesiol. Scand.
2004, 48, 799–813. [CrossRef]
16. Kleiman, A.; Tuckermann, J.P. Glucocorticoid receptor action in beneficial and side effects of steroid therapy: Lessons from
conditional knockout mice. Mol. Cell. Endocrinol. 2007, 275, 98–108. [CrossRef]
17. Newton, R.; Shah, S.; Altonsy, M.O.; Gerber, A.N. Glucocorticoid and cytokine crosstalk: Feedback, feedforward, and co-regulatory
interactions determine repression or resistance. J. Biol. Chem. 2017, 292, 7163–7172. [CrossRef]
18. De Bosscher, K. Selective Glucocorticoid Receptor modulators. J. Steroid Biochem. Mol. Biol. 2010, 120, 96–104. [CrossRef]
19. Chatzopoulou, A.; Schoonheim, P.J.; Torraca, V.; Meijer, A.H.; Spaink, H.; Schaaf, M.J. Functional analysis reveals no transcriptional
role for the glucocorticoid receptor β-isoform in zebrafish. Mol. Cell. Endocrinol. 2017, 447, 61–70. [CrossRef]
20. Schaaf, M.J.M.; Champagne, D.; van Laanen, I.H.C.; van Wijk, D.C.W.A.; Meijer, A.H.; Meijer, O.C.; Spaink, H.P.; Richardson,
M.K. Discovery of a Functional Glucocorticoid Receptor β-Isoform in Zebrafish. Endocrinology 2007, 149, 1591–1599. [CrossRef]
[PubMed]
21. Jones, M.T.; Hillhouse, E.W.; Burden, J.L. Dynamics and mechanics of corticosteroid feedback at the hypothalamus and anterior
pituitary gland. J. Endocrinol. 1977, 73, 405–417. [CrossRef]
22. Dallman, M.F.; Akana, S.F.; Jacobson, L.; Levin, N.; Cascio, C.S.; Shinsako, J. Characterization of Corticosterone Feedback
Regulation of ACTH Secretion. Ann. N. Y. Acad. Sci. 1987, 512, 402–414. [CrossRef]
23. Alsop, D.; Vijayan, M.M. Development of the corticosteroid stress axis and receptor expression in zebrafish. Am. J. Physiol. Regul.
Integr. Comp. Physiol. 2008, 294, R711–R719. [CrossRef]
24. Yamamoto, K.R. Steroid receptor regulated transcription of specific genes and gene networks. Annu. Rev. Genet. 1985, 19, 209–252.
[CrossRef]
25. Hollenberg, S.M.; Weinberger, C.; Ong, E.S.; Cerelli, G.; Oro, A.; Lebo, R.; Thompson, E.B.; Rosenfeld, M.G.; Evans, R. Primary
structure and expression of a functional human glucocorticoid receptor cDNA. Nature 1985, 318, 635–641. [CrossRef]
26. Miesfeld, R.; Rusconi, S.; Godowski, P.J.; Maler, B.A.; Okret, S.; Wikström, A.-C.; Gustafsson, J.; Yamamoto, K.R. Genetic
complementation of a glucocorticoid receptor deficiency by expression of cloned receptor cDNA. Cell 1986, 46, 389–399. [CrossRef]
27. Jonat, C.; Rahmsdorf, H.J.; Park, K.-K.; Cato, A.; Gebel, S.; Ponta, H.; Herrlich, P. Antitumor promotion and antiinflammation:
Down-modulation of AP-1 (Fos/Jun) activity by glucocorticoid hormone. Cell 1990, 62, 1189–1204. [CrossRef]
28. Heck, S.; Kullmann, M.; Gast, A.; Ponta, H.; Rahmsdorf, H.; Herrlich, P.; Cato, A. A distinct modulating domain in glucocorticoid
receptor monomers in the repression of activity of the transcription factor AP-1. EMBO J. 1994, 13, 4087–4095. [CrossRef]
29. Heck, S.; Bender, K.; Kullmann, M.; Göttlicher, M.; Herrlich, P.; Cato, A.C. Ikappa Balpha -independent downregulation of
NF-kappa B activity by glucocorticoid receptor. EMBO J. 1997, 16, 4698–4707. [CrossRef]
30. Yang-Yen, H.-F.; Chambard, J.C.; Sun, Y.-L.; Smeal, T.; Schmidt, T.; Drouin, J.; Karin, M. Transcriptional interference between
c-Jun and the glucocorticoid receptor: Mutual inhibition of DNA binding due to direct protein-protein interaction. Cell 1990,
62, 1205–1215. [CrossRef]
31. Nikolaus, S.; Fölscn, U.; Schreiber, S. Immunopharmacology of 5-aminosalicylic acid and of glucocorticoids in the therapy of
inflammatory bowel disease. Hepatogastroenterology 2000, 47, 71–82.
32. Neeck, G.; Renkawitz, R.; Eggert, M. Molecular aspects of glucocorticoid hormone action in rheumatoid arthritis. Cytokines Cell.
Mol. Ther. 2002, 7, 61–69. [CrossRef] [PubMed]
33. Chrousos, G.P.; Kino, T. Intracellular Glucocorticoid Signaling: A Formerly Simple System Turns Stochastic. Sci. STKE 2005,
2005, pe48. [CrossRef]
34. Revollo, J.R.; Cidlowski, J.A. Mechanisms Generating Diversity in Glucocorticoid Receptor Signaling. Ann. N. Y. Acad. Sci. 2009,
1179, 167–178. [CrossRef]
35. Busillo, J.M.; Cidlowski, J.A. The five Rs of glucocorticoid action during inflammation: Ready, reinforce, repress, resolve, and
restore. Trends Endocrinol. Metab. 2013, 24, 109–119. [CrossRef]
36. Reichardt, S.D.; Amouret, A.; Muzzi, C.; Vettorazzi, S.; Tuckermann, J.P.; Lühder, F.; Reichardt, H.M. The Role of Glucocorticoids
in Inflammatory Diseases. Cells 2021, 10, 2921. [CrossRef]
37. Van Staa, T.P.; Leufkens, H.G.M.; Abenhaim, L.; Begaud, B.; Zhang, B.; Cooper, C. Use of oral corticosteroids in the United
Kingdom. QJM Int. J. Med. 2000, 93, 105–111. [CrossRef]
38. Moghadam-Kia, S.; Werth, V.P. Prevention and treatment of systemic glucocorticoid side effects. Int. J. Dermatol. 2010, 49, 239–248.
[CrossRef] [PubMed]
Cells 2021, 10, 3441 19 of 27
39. Barnes, P.J.; Adcock, I. Glucocorticoid resistance in inflammatory diseases. Lancet 2009, 373, 1905–1917. [CrossRef]
40. Barnes, P.J. Glucocorticosteroids: Current and future directions. Br. J. Pharmacol. 2010, 163, 29–43. [CrossRef]
41. Schaaf, M.J.; Cidlowski, J.A. Molecular mechanisms of glucocorticoid action and resistance. J. Steroid Biochem. Mol. Biol. 2002,
83, 37–48. [CrossRef]
42. Spies, L.-M.L.; Verhoog, N.J.D.; Louw, A. Acquired Glucocorticoid Resistance Due to Homologous Glucocorticoid Receptor
Downregulation: A Modern Look at an Age-Old Problem. Cells 2021, 10, 2529. [CrossRef]
43. Howell, M.P.; Muglia, L.J. Effects of genetically altered brain glucocorticoid receptor action on behavior and adrenal axis
regulation in mice. Front. Neuroendocrinol. 2006, 27, 275–284. [CrossRef]
44. Zappia, C.D.; Torralba-Agu, V.; Echeverria, E.; Fitzsimons, C.P.; Fernández, N.; Monczor, F. Antihistamines Potentiate Dexametha-
sone Anti-Inflammatory Effects. Impact on Glucocorticoid Receptor-Mediated Expression of Inflammation-Related Genes. Cells
2021, 10, 3026. [CrossRef] [PubMed]
45. Bamberger, C.M.; Schulte, H.M.; Chrousos, G.P. Molecular Determinants of Glucocorticoid Receptor Function and Tissue
Sensitivity to Glucocorticoids. Endocr. Rev. 1996, 17, 245–261. [CrossRef]
46. Faught, E.; Vijayan, M.M. Maternal stress and fish reproduction: The role of cortisol revisited. Fish Fish. 2018, 19, 1016–1030.
[CrossRef]
47. Gomez-Sanchez, E.; Gomez-Sanchez, C.E. The Multifaceted Mineralocorticoid Receptor. Compr. Physiol. 2014, 4, 965–994.
[CrossRef]
48. Spach, C.; Streeten, D.H.P. Retardation of Sodium Exchange in Dog Erythrocytes by Physiological Concentrations of Aldosterone,
in Vitro. J. Clin. Investig. 1964, 43, 217–227. [CrossRef]
49. Moura, A.M.; Worcel, M. Direct action of aldosterone on transmembrane 22Na efflux from arterial smooth muscle. Rapid and
delayed effects. Hypertension 1984, 6, 425–430. [CrossRef] [PubMed]
50. Buttgereit, F.; Wehling, M.; Burmester, G.R. A new hypothesis of modular glucocorticoid actions: Steroid treatment of rheumatic
diseases revisited. Arthritis Rheum. 1998, 41, 761–767. [CrossRef]
51. Buttgereit, F.; Scheffold, A. Rapid glucocorticoid effects on immune cells. Steroids 2002, 67, 529–534. [CrossRef]
52. Pereda, M.P.; Lohrer, P.; Kovalovsky, D.; Castro, C.P.; Goldberg, V.; Losa, M.; Chervin, A.; Berner, S.; Molina, H.; Stalla, G.K.;
et al. Interleukin-6 is inhibited by glucocorticoids and stimulates ACTH secretion and POMC expression in human corticotroph
pituitary adenomas. Exp. Clin. Endocrinol. Diabetes 2000, 108, 202–207. [CrossRef] [PubMed]
53. Cruz-Topete, D.; Cidlowski, J. One Hormone, Two Actions: Anti- and Pro-Inflammatory Effects of Glucocorticoids. Neuroim-
munomodulation 2015, 22, 20–32. [CrossRef] [PubMed]
54. Arnett, M.G.; Muglia, L.M.; Laryea, G.; Muglia, L.J. Genetic Approaches to Hypothalamic-Pituitary-Adrenal Axis Regulation.
Neuropsychopharmacology 2015, 41, 245–260. [CrossRef] [PubMed]
55. Bertini, R.; Bianchi, M.; Ghezzi, P. Adrenalectomy sensitizes mice to the lethal effects of interleukin 1 and tumor necrosis factor.
J. Exp. Med. 1988, 167, 1708–1712. [CrossRef]
56. Edwards, C.K., 3rd; Yunger, L.M.; Lorence, R.M.; Dantzer, R.; Kelley, K.W. The pituitary gland is required for protection against
lethal effects of Salmonella typhimurium. Proc. Natl. Acad. Sci. USA 1991, 88, 2274–2277. [CrossRef] [PubMed]
57. Macphee, I.A.M.; Antoni, F.A.; Mason, D.W. Spontaneous recovery of rats from experimental allergic encephalomyelitis is
dependent on regulation of the immune system by endogenous adrenal corticosteroids. J. Exp. Med. 1989, 169, 431–445.
[CrossRef] [PubMed]
58. Ramachandra, R.N. Neuro-hormonal host defence in endotoxin shock. Brain Behav. Immun. 1992, 6, 157–169. [CrossRef]
59. Refojo, D.; Liberman, A.C.; Giacomini, D.; Nagashima, A.C.; Graciarena, M.; Echenique, C.; Pereda, M.P.; Stalla, G.; Holsboer, F.;
Arzt, E. Integrating Systemic Information at the Molecular Level: Cross-talk between steroid receptors and cytokine signaling on
different target cells. Ann. N. Y. Acad. Sci. 2003, 992, 196–204. [CrossRef] [PubMed]
60. Ruzek, M.C.; Pearce, B.D.; Miller, A.H.; Biron, C.A. Endogenous glucocorticoids protect against cytokine-mediated lethality
during viral infection. J. Immunol. 1999, 162, 3527–3533.
61. Silverman, M.N.; Sternberg, E.M. Glucocorticoid regulation of inflammation and its functional correlates: From HPA axis to
glucocorticoid receptor dysfunction. Ann. N. Y. Acad. Sci. 2012, 1261, 55–63. [CrossRef]
62. Smith, S.M.; Vale, W.W. The role of the hypothalamic-pituitary-adrenal axis in neuroendocrine responses to stress. Dialog. Clin.
Neurosci. 2006, 8, 383–395.
63. De Guia, R.; Rose, A.J.; Herzig, S. Glucocorticoid hormones and energy homeostasis. Horm. Mol. Biol. Clin. Investig. 2014,
19, 117–128. [CrossRef] [PubMed]
64. Katsu, Y.; Iguchi, T. Subchapter 95D—Cortisol. In Handbook of Hormones; Takei, Y., Ando, H., Tsutsui, K., Eds.; Academic Press:
San Diego, CA, USA, 2016; pp. 532–533. [CrossRef]
65. Cummins, E.P.; Taylor, C.T. Hypoxia-responsive transcription factors. Pflügers Arch. 2005, 450, 363–371. [CrossRef]
66. Bertout, J.A.; Patel, S.A.; Simon, M.C. The impact of O2 availability on human cancer. Nat. Rev. Cancer 2008, 8, 967–975. [CrossRef]
[PubMed]
67. Dougherty, E.J.; Pollenz, R.S. ARNT: A Key bHLH/PAS Regulatory Protein Across Multiple Pathways. Compr. Toxicol. 2010,
2, 231–252. [CrossRef]
68. Pelster, B.; Egg, M. Hypoxia-inducible transcription factors in fish: Expression, function and interconnection with the circadian
clock. J. Exp. Biol. 2018, 221, jeb163709. [CrossRef]
Cells 2021, 10, 3441 20 of 27
69. Hill, A.J.; Heiden, T.C.K.; Heideman, W.; Peterson, R.E. Potential Roles of Arnt2 in Zebrafish Larval Development. Zebrafish 2009,
6, 79–91. [CrossRef] [PubMed]
70. Prasch, A.L.; Tanguay, R.L.; Mehta, V.; Heideman, W.; Peterson, R.E. Identification of Zebrafish ARNT1 Homologs: 2,3,7,8-
Tetrachlorodibenzo-p-dioxin Toxicity in the Developing Zebrafish Requires ARNT1. Mol. Pharmacol. 2005, 69, 776–787. [CrossRef]
[PubMed]
71. Elks, P.M.; Renshaw, S.; Meijer, A.H.; Walmsley, S.; van Eeden, F.J. Exploring the HIFs, buts and maybes of hypoxia signalling in
disease: Lessons from zebrafish models. Dis. Model. Mech. 2015, 8, 1349–1360. [CrossRef] [PubMed]
72. Semenza, G.L. Hypoxia-Inducible Factors in Physiology and Medicine. Cell 2012, 148, 399–408. [CrossRef] [PubMed]
73. Lando, D.; Peet, D.J.; Gorman, J.J.; Whelan, D.A.; Whitelaw, M.L.; Bruick, R.K. FIH-1 is an asparaginyl hydroxylase enzyme that
regulates the transcriptional activity of hypoxia-inducible factor. Genes Dev. 2002, 16, 1466–1471. [CrossRef] [PubMed]
74. van Rooijen, E.; Voest, E.E.; Logister, I.; Korving, J.; Schwerte, T.; Schulte-Merker, S.; Giles, R.H.; van Eeden, F.J. Zebrafish mutants
in the von Hippel-Lindau tumor suppressor display a hypoxic response and recapitulate key aspects of Chuvash polycythemia.
Blood 2009, 113, 6449–6460. [CrossRef] [PubMed]
75. Pescador, N.; Cuevas, Y.; Naranjo, S.; Alcaide, M.; Villar, D.; Landázuri, M.O.; del Peso, L. Identification of a functional hypoxia-
responsive element that regulates the expression of the egl nine homologue 3 (egln3/phd3) gene. Biochem. J. 2005, 390, 189–197.
[CrossRef] [PubMed]
76. Santhakumar, K.; Judson, E.C.; Elks, P.M.; McKee, S.; Elworthy, S.; Van Rooijen, E.; Walmsley, S.S.; Renshaw, S.A.; Cross, S.S.;
Van Eeden, F.J. A Zebrafish Model to Study and Therapeutically Manipulate Hypoxia Signaling in Tumorigenesis. Cancer Res.
2012, 72, 4017–4027. [CrossRef]
77. Basu, M.; Sawhney, R.C.; Kumar, S.; Pal, K.; Prasad, R.; Selvamurthy, W. Glucocorticoids as prophylaxis against acute mountain
sickness. Clin. Endocrinol. 2002, 57, 761–767. [CrossRef]
78. Leonard, M.O.; Godson, C.; Brady, H.R.; Taylor, C. Potentiation of Glucocorticoid Activity in Hypoxia through Induction of the
Glucocorticoid Receptor. J. Immunol. 2005, 174, 2250–2257. [CrossRef] [PubMed]
79. Kodama, T.; Shimizu, N.; Yoshikawa, N.; Makino, Y.; Ouchida, R.; Okamoto, K.; Hisada, T.; Nakamura, H.; Morimoto, C.;
Tanaka, H. Role of the Glucocorticoid Receptor for Regulation of Hypoxia-dependent Gene Expression. J. Biol. Chem. 2003,
278, 33384–33391. [CrossRef] [PubMed]
80. Wagner, A.; Huck, G.; Stiehl, D.; Jelkmann, W.; Hellwig-Bürgel, T. Dexamethasone impairs hypoxia-inducible factor-1 function.
Biochem. Biophys. Res. Commun. 2008, 372, 336–340. [CrossRef] [PubMed]
81. Sun, Y.-Y.; Wang, C.-Y.; Hsu, M.-F.; Juan, S.-H.; Chang, C.-Y.; Chou, C.-M.; Yang, L.-Y.; Hung, K.-S.; Xu, J.; Lee, Y.-H.; et al.
Glucocorticoid Protection of Oligodendrocytes against Excitotoxin Involving Hypoxia-Inducible Factor-1 in a Cell-Type-Specific
Manner. J. Neurosci. 2010, 30, 9621–9630. [CrossRef] [PubMed]
82. Elks, P.; Van Eeden, F.J.; Dixon, G.; Wang, X.; Reyes-Aldasoro, C.C.; Ingham, P.W.; Whyte, M.K.B.; Walmsley, S.; Renshaw, S.A.
Activation of hypoxia-inducible factor-1α (Hif-1α) delays inflammation resolution by reducing neutrophil apoptosis and reverse
migration in a zebrafish inflammation model. Blood 2011, 118, 712–722. [CrossRef] [PubMed]
83. van Rooijen, E.; Santhakumar, K.; Logister, I.; Voest, E.; Schulte-Merker, S.; Giles, R.; van Eeden, F. A Zebrafish Model for VHL
and Hypoxia Signaling. Apoptosis 2011, 105, 163–190. [CrossRef]
84. Schoonheim, P.J.; Chatzopoulou, A.; Schaaf, M.J. The zebrafish as an in vivo model system for glucocorticoid resistance. Steroids
2010, 75, 918–925. [CrossRef] [PubMed]
85. Schaaf, M.; Chatzopoulou, A.; Spaink, H. The zebrafish as a model system for glucocorticoid receptor research. Comp. Biochem.
Physiol. Part A Mol. Integr. Physiol. 2009, 153, 75–82. [CrossRef] [PubMed]
86. Hammond, F.R.; Lewis, A.; Elks, P.M. If it’s not one thing, HIF’s another: Immunoregulation by hypoxia inducible factors in
disease. FEBS J. 2020, 287, 3907–3916. [CrossRef] [PubMed]
87. Ziv, L.; Muto, A.; Schoonheim, P.J.; Meijsing, S.H.; Strasser, D.; Ingraham, H.A.; Schaaf, M.J.M.; Yamamoto, K.R.; Baier, H.
An affective disorder in zebrafish with mutation of the glucocorticoid receptor. Mol. Psychiatry 2012, 18, 681–691. [CrossRef]
[PubMed]
88. Robertson, A.L.; Holmes, G.R.; Bojarczuk, A.N.; Burgon, J.; Loynes, C.A.; Chimen, M.; Sawtell, A.K.; Hamza, B.; Willson,
J.; Walmsley, S.R.; et al. A Zebrafish Compound Screen Reveals Modulation of Neutrophil Reverse Migration as an Anti-
Inflammatory Mechanism. Sci. Transl. Med. 2014, 6, 225ra29. [CrossRef]
89. Hruscha, A.; Krawitz, P.; Rechenberg, A.; Heinrich, V.; Hecht, J.; Haass, C.; Schmid, B. Efficient CRISPR/Cas9 genome editing
with low off-target effects in zebrafish. Development 2013, 140, 4982–4987. [CrossRef] [PubMed]
90. Varshney, G.K.; Pei, W.; LaFave, M.C.; Idol, J.; Xu, L.; Gallardo, V.; Carrington, B.; Bishop, K.; Jones, M.; Li, M.; et al. High-
throughput gene targeting and phenotyping in zebrafish using CRISPR/Cas9. Genome Res. 2015, 25, 1030–1042. [CrossRef]
[PubMed]
91. Doudna, J.A.; Charpentier, E. Genome editing. The new frontier of genome engineering with CRISPR-Cas9. Science 2014,
346, 1258096. [CrossRef] [PubMed]
92. Nesan, D.; Vijayan, M.M. Maternal Cortisol Mediates Hypothalamus-Pituitary-Interrenal Axis Development in Zebrafish. Sci.
Rep. 2016, 6, 22582. [CrossRef] [PubMed]
93. Tsigos, C.; Chrousos, G.P. Hypothalamic–pituitary–adrenal axis, neuroendocrine factors and stress. J. Psychosom. Res. 2002,
53, 865–871. [CrossRef]
Cells 2021, 10, 3441 21 of 27
94. Schmidt, F.; Braunbeck, T. Alterations along the Hypothalamic-Pituitary-Thyroid Axis of the Zebrafish (Danio rerio) after
Exposure to Propylthiouracil. J. Thyroid. Res. 2011, 2011, 376243. [CrossRef]
95. Gonzalez-Nunez, V. Identification of two proopiomelanocortin genes in zebrafish (Danio rerio). Mol. Brain Res. 2003, 120, 1–8.
[CrossRef] [PubMed]
96. Hansen, I.A.; To, T.T.; Wortmann, S.; Burmester, T.; Winkler, C.; Meyer, S.R.; Neuner, C.; Fassnacht, M.; Allolio, B. The pro-
opiomelanocortin gene of the zebrafish (Danio rerio). Biochem. Biophys. Res. Commun. 2003, 303, 1121–1128. [CrossRef]
97. To, T.T.; Hahner, S.; Nica, G.; Rohr, K.B.; Hammerschmidt, M.; Winkler, C.; Allolio, B. Pituitary-Interrenal Interaction in Zebrafish
Interrenal Organ Development. Mol. Endocrinol. 2007, 21, 472–485. [CrossRef] [PubMed]
98. Wagle, M.; Mathur, P.; Guo, S. Corticotropin-Releasing Factor Critical for Zebrafish Camouflage Behavior Is Regulated by Light
and Sensitive to Ethanol. J. Neurosci. 2011, 31, 214–224. [CrossRef]
99. Shi, C.; Lu, Y.; Zhai, G.; Huang, J.; Shang, G.; Lou, Q.; Li, D.; Jin, X.; He, J.; Du, Z.; et al. Hyperandrogenism in POMCa-deficient
zebrafish enhances somatic growth without increasing adiposity. J. Mol. Cell Biol. 2019, 12, 291–304. [CrossRef] [PubMed]
100. Mommsen, T.P.; Vijayan, M.M.; Moon, T.W. Cortisol in teleosts: Dynamics, mechanisms of action, and metabolic regulation. Rev.
Fish Biol. Fish. 1999, 9, 211–268. [CrossRef]
101. Nesan, D.; Vijayan, M.M. Role of glucocorticoid in developmental programming: Evidence from zebrafish. Gen. Comp. Endocrinol.
2013, 181, 35–44. [CrossRef]
102. Spiga, F.; Walker, J.J.; Terry, J.R.; Lightman, S.L. HPA Axis-Rhythms. Compr. Physiol. 2014, 4, 1273–1298. [CrossRef]
103. Ramamoorthy, S.; Cidlowski, J.A. Corticosteroids. Mechanisms of Action in Health and Disease. Rheum. Dis. Clin. N. Am. 2016,
42, 15–31. [CrossRef]
104. Gjerstad, J.K.; Lightman, S.L.; Spiga, F. Role of glucocorticoid negative feedback in the regulation of HPA axis pulsatility. Stress
2018, 21, 403–416. [CrossRef]
105. Dallman, M.F.; Akana, S.F.; Cascio, C.S.; Darlington, D.N.; Jacobson, L.; Levin, N. Regulation of ACTH Secretion: Variations on a
Theme of B. Recent Prog. Horm. Res. 1987, 43, 113–173. [CrossRef] [PubMed]
106. Drouin, J.; Trifiro, M.A.; Plante, R.K.; Nemer, M.; Eriksson, P.; Wrange, O. Glucocorticoid receptor binding to a specific DNA
sequence is required for hormone-dependent repression of pro-opiomelanocortin gene transcription. Mol. Cell. Biol. 1989,
9, 5305–5314. [CrossRef]
107. Ulrich-Lai, Y.; Herman, J. Neural regulation of endocrine and autonomic stress responses. Nat. Rev. Neurosci. 2009, 10, 397–409.
[CrossRef]
108. Nicolaides, N.C.; Galata, Z.; Kino, T.; Chrousos, G.P.; Charmandari, E. The human glucocorticoid receptor: Molecular basis of
biologic function. Steroids 2010, 75, 1–12. [CrossRef]
109. Nicolaides, N.C.; Kyratzi, E.; Lamprokostopoulou, A.; Chrousos, G.P.; Charmandari, E. Stress, the Stress System and the Role of
Glucocorticoids. Neuroimmunomodulation 2015, 22, 6–19. [CrossRef]
110. Mangelsdorf, D.J.; Thummel, C.; Beato, M.; Herrlich, P.; Schütz, G.; Umesono, K.; Blumberg, B.; Kastner, P.; Mark, M.; Chambon,
P.; et al. The nuclear receptor superfamily: The second decade. Cell 1995, 83, 835–839. [CrossRef]
111. De Kloet, E.R.; Joels, M.; Holsboer, F. Stress and the brain: From adaptation to disease. Nat. Rev. Neurosci. 2005, 6, 463–475.
[CrossRef]
112. Schoneveld, O.J.; Gaemers, I.C.; Lamers, W.H. Mechanisms of glucocorticoid signalling. Biochim. Biophys. Acta (BBA) Gene Struct.
Expr. 2004, 1680, 114–128. [CrossRef]
113. Oakley, R.H.; Cidlowski, J.A. The Biology of the Glucocorticoid Receptor: New Signaling Mechanism in Health and Disease.
J. Allergy Clin. Inmunol. 2013, 132, 1033–1044. [CrossRef]
114. Evans, R.M. The steroid and thyroid hormone receptor superfamily. Science 1988, 240, 889–895. [CrossRef]
115. Kumar, R.; Thompson, E.B. Gene regulation by the glucocorticoid receptor: Structure:function relationship. J. Steroid Biochem.
Mol. Biol. 2005, 94, 383–394. [CrossRef]
116. Glass, C.K.; Rose, D.W.; Rosenfeld, M.G. Nuclear receptor coactivators. Curr. Opin. Cell Biol. 1997, 9, 222–232. [CrossRef]
117. Beck, I.; Berghe, W.V.; Vermeulen, L.; Yamamoto, K.R.; Haegeman, G.; De Bosscher, K. Crosstalk in Inflammation: The Interplay
of Glucocorticoid Receptor-Based Mechanisms and Kinases and Phosphatases. Endocr. Rev. 2009, 30, 830–882. [CrossRef]
118. Bledsoe, R.K.; Montana, V.G.; Stanley, T.B.; Delves, C.J.; Apolito, C.J.; McKee, D.D.; Consler, T.G.; Parks, D.J.; Stewart, E.L.;
Willson, T.M.; et al. Crystal Structure of the Glucocorticoid Receptor Ligand Binding Domain Reveals a Novel Mode of Receptor
Dimerization and Coactivator Recognition. Cell 2002, 110, 93–105. [CrossRef]
119. Yudt, M.R.; Cidlowski, J.A. Molecular Identification and Characterization of A and B Forms of the Glucocorticoid Receptor. Mol.
Endocrinol. 2001, 15, 1093–1103. [CrossRef]
120. Yudt, M.R.; Cidlowski, J. The Glucocorticoid Receptor: Coding a Diversity of Proteins and Responses through a Single Gene. Mol.
Endocrinol. 2002, 16, 1719–1726. [CrossRef]
121. Oakley, R.H.; Cidlowski, J.A. Cellular Processing of the Glucocorticoid Receptor Gene and Protein: New Mechanisms for
Generating Tissue-specific Actions of Glucocorticoids. J. Biol. Chem. 2011, 286, 3177–3184. [CrossRef]
122. Merkulov, V.M.; Merkulova, T.I. Glucocorticoid receptor isoforms generated by alternative splicing and alternative translation
initiation. Russ. J. Genet. Appl. Res. 2012, 2, 205–213. [CrossRef]
123. Rafacho, A.; Ortsäter, H.; Nadal, A.; Quesada, I. Glucocorticoid treatment and endocrine pancreas function: Implications for
glucose homeostasis, insulin resistance and diabetes. J. Endocrinol. 2014, 223, R49–R62. [CrossRef]
Cells 2021, 10, 3441 22 of 27
124. Marchi, D. Bidirectional Crosstalk between Hypoxia-Inducible Factor and Glucocorticoid Signalling in Zebrafish Larvae. Univer-
sity of Sheffield. 2020. Available online: https://etheses.whiterose.ac.uk/28224/ (accessed on 2 December 2021).
125. Encío, I.J.; Detera-Wadleigh, S.D. The genomic structure of the human glucocorticoid receptor. J. Biol. Chem. 1991, 266, 7182–7188.
[CrossRef]
126. Yudt, M.R.; Jewell, C.M.; Bienstock, R.; Cidlowski, J.A. Molecular Origins for the Dominant Negative Function of Human
Glucocorticoid Receptor Beta. Mol. Cell. Biol. 2003, 23, 4319–4330. [CrossRef] [PubMed]
127. Oakley, R.H.; Sar, M.; Cidlowski, J.A. The Human Glucocorticoid Receptor β Isoform: Expression, biochemical properties, and
putative function. J. Biol. Chem. 1996, 271, 9550–9559. [CrossRef]
128. Bamberger, C.M.; Bamberger, A.M.; de Castro, M.; Chrousos, G.P. Glucocorticoid receptor beta, a potential endogenous inhibitor
of glucocorticoid action in humans. J. Clin. Investig. 1995, 95, 2435–2441. [CrossRef]
129. Oakley, R.H.; Jewell, C.M.; Yudt, M.R.; Bofetiado, D.M.; Cidlowski, J. The Dominant Negative Activity of the Human Glu-
cocorticoid Receptor β Isoform. Specificity and mechanisms of action. J. Biol. Chem. 1999, 274, 27857–27866. [CrossRef]
[PubMed]
130. Charmandari, E.; Chrousos, G.P.; Ichijo, T.; Bhattacharyya, N.; Vottero, A.; Souvatzoglou, E.; Kino, T. The Human Glucocorticoid
Receptor (hGR) β Isoform Suppresses the Transcriptional Activity of hGRα by Interfering with Formation of Active Coactivator
Complexes. Mol. Endocrinol. 2005, 19, 52–64. [CrossRef] [PubMed]
131. Hauk, P.J.; Goleva, E.; Strickland, I.; Vottero, A.; Chrousos, G.P.; Kisich, K.O.; Leung, D.Y.M. Increased Glucocorticoid
ReceptorβExpression Converts Mouse Hybridoma Cells to a Corticosteroid-Insensitive Phenotype. Am. J. Respir. Cell Mol. Biol.
2002, 27, 361–367. [CrossRef] [PubMed]
132. Strickland, I.; Kisich, K.; Hauk, P.J.; Vottero, A.; Chrousos, G.P.; Klemm, D.J.; Leung, D.Y. High Constitutive Glucocorticoid
Receptor β in Human Neutrophils Enables Them to Reduce Their Spontaneous Rate of Cell Death in Response to Corticosteroids.
J. Exp. Med. 2001, 193, 585–594. [CrossRef]
133. Timmermans, S.; Souffriau, J.; Libert, C. A General Introduction to Glucocorticoid Biology. Front. Immunol. 2019, 10, 1545.
[CrossRef]
134. Lewis-Tuffin, L.J.; Jewell, C.M.; Bienstock, R.; Collins, J.B.; Cidlowski, J. Human Glucocorticoid Receptor β Binds RU-486 and Is
TranscriptionallyActive. Mol. Cell. Biol. 2007, 27, 2266–2282. [CrossRef]
135. Kino, T.; Manoli, I.; Kelkar, S.; Wang, Y.; Su, Y.A.; Chrousos, G.P. Glucocorticoid receptor (GR) β has intrinsic, GRα-independent
transcriptional activity. Biochem. Biophys. Res. Commun. 2009, 381, 671–675. [CrossRef]
136. Honda, M.; Orii, F.; Ayabe, T.; Imai, S.; Ashida, T.; Obara, T.; Kohgo, Y. Expression of glucocorticoid receptor β in lymphocytes of
patients with glucocorticoid-resistant ulcerative colitis. Gastroenterology 2000, 118, 859–866. [CrossRef]
137. Shahidi, H.; Vottero, A.; Stratakis, C.A.; Taymans, S.E.; Karl, M.; Longui, C.A.; Chrousos, G.P.; Daughaday, W.H.; Gregory, S.A.;
Plate, J.M. Imbalanced Expression of the Glucocorticoid Receptor Isoforms in Cultured Lymphocytes from a Patient with Systemic
Glucocorticoid Resistance and Chronic Lymphocytic Leukemia. Biochem. Biophys. Res. Commun. 1999, 254, 559–565. [CrossRef]
138. Bergeron, C.; Fukakusa, M.; Olivenstein, R.; Lemiere, C.; Shannon, J.; Ernst, P.; Martin, J.G.; Hamid, Q. Increased glucocorticoid
receptor–β expression, but not decreased histone deacetylase 2, in severe asthma. J. Allergy Clin. Immunol. 2006, 117, 703–705.
[CrossRef]
139. Hamid, Q.A.; Wenzel, S.E.; Hauk, P.J.; Tsicopoulos, A.; Wallaert, B.; Lafitte, J.-J.; Chrousos, G.P.; Szefler, S.J.; Leung, D.Y.M.
Increased Glucocorticoid Receptor β in Airway Cells of Glucocorticoid-insensitive Asthma. Am. J. Respir. Crit. Care Med. 1999,
159, 1600–1604. [CrossRef]
140. Goleva, E.; Li, L.-B.; Eves, P.T.; Strand, M.; Martin, R.J.; Leung, D.Y.M. Increased Glucocorticoid Receptor β Alters Steroid
Response in Glucocorticoid-insensitive Asthma. Am. J. Respir. Crit. Care Med. 2006, 173, 607–616. [CrossRef]
141. Leung, D.Y.; Hamid, Q.; Vottero, A.; Szefler, S.J.; Surs, W.; Minshall, E.; Chrousos, G.P.; Klemm, D.J. Association of Glucocorticoid
Insensitivity with Increased Expression of Glucocorticoid Receptor β. J. Exp. Med. 1997, 186, 1567–1574. [CrossRef]
142. Chatzopoulou, A.; Roy, U.; Meijer, A.H.; Alia, A.; Spaink, H.; Schaaf, M.J.M. Transcriptional and Metabolic Effects of Glucocorti-
coid Receptor α and β Signaling in Zebrafish. Endocrinology 2015, 156, 1757–1769. [CrossRef]
143. Ramos-Ramírez, P.; Tliba, O. Glucocorticoid Receptor β (GRβ): Beyond Its Dominant-Negative Function. Int. J. Mol. Sci. 2021,
22, 3649. [CrossRef]
144. Holownia, A.; Mroz, R.M.; Kolodziejczyk, A.; Chyczewska, E.; Braszko, J.J. Increased FKBP51 in induced sputum cells of chronic
obstructive pulmonary disease patients after therapy. Eur. J. Med. Res. 2009, 14 (Suppl. 4), 108–111. [CrossRef]
145. Storer, C.L.; Dickey, C.A.; Galigniana, M.D.; Rein, T.; Cox, M.B. FKBP51 and FKBP52 in signaling and disease. Trends Endocrinol.
Metab. 2011, 22, 481–490. [CrossRef]
146. Woodruff, P.G.; Boushey, H.A.; Dolganov, G.M.; Barker, C.S.; Yang, J.; Donnelly, S.; Ellwanger, A.; Sidhu, S.S.; Dao-Pick, T.P.;
Pantoja, C.; et al. Genome-wide profiling identifies epithelial cell genes associated with asthma and with treatment response to
corticosteroids. Proc. Natl. Acad. Sci. USA 2007, 104, 15858–15863. [CrossRef]
147. Binder, E.B. The role of FKBP5, a co-chaperone of the glucocorticoid receptor in the pathogenesis and therapy of affective and
anxiety disorders. Psychoneuroendocrinology 2009, 34, S186–S195. [CrossRef]
148. Liberman, A.C.; Budziñski, M.L.; Sokn, C.; Gobbini, R.P.; Steininger, A.; Arzt, E. Regulatory and Mechanistic Actions of
Glucocorticoids on T and Inflammatory Cells. Front. Endocrinol. 2018, 9, 235. [CrossRef]
Cells 2021, 10, 3441 23 of 27
149. Vandevyver, S.; Dejager, L.; Tuckermann, J.; Libert, C. New Insights into the Anti-inflammatory Mechanisms of Glucocorticoids:
An Emerging Role for Glucocorticoid-Receptor-Mediated Transactivation. Endocrinology 2013, 154, 993–1007. [CrossRef]
150. Presman, D.M.; Hager, G.L. More than meets the dimer: What is the quaternary structure of the glucocorticoid receptor?
Transcription 2016, 8, 32–39. [CrossRef]
151. Reichardt, H.M.; Kaestner, K.H.; Tuckermann, J.; Kretz, O.; Wessely, O.; Bock, R.; Gass, P.; Schmid, W.; Herrlich, P.; Angel, P.; et al.
DNA Binding of the Glucocorticoid Receptor Is Not Essential for Survival. Cell 1998, 93, 531–541. [CrossRef]
152. Prager, E.M.; Johnson, L.R. Stress at the Synapse: Signal Transduction Mechanisms of Adrenal Steroids at Neuronal Membranes.
Sci. Signal. 2009, 2, re5. [CrossRef]
153. Groeneweg, F.L.; Karst, H.; de Kloet, R.; Joels, M. Rapid non-genomic effects of corticosteroids and their role in the central stress
response. J. Endocrinol. 2011, 209, 153–167. [CrossRef] [PubMed]
154. Uhlenhaut, H.; Barish, G.D.; Yu, R.T.; Downes, M.; Karunasiri, M.; Liddle, C.; Schwalie, P.C.; Hübner, N.; Evans, R.M. Insights
into Negative Regulation by the Glucocorticoid Receptor from Genome-wide Profiling of Inflammatory Cistromes. Mol. Cell 2012,
49, 158–171. [CrossRef] [PubMed]
155. Guenther, M.G.; Barak, O.; Lazar, M.A. The SMRT and N-CoR Corepressors Are Activating Cofactors for Histone Deacetylase 3.
Mol. Cell. Biol. 2001, 21, 6091–6101. [CrossRef]
156. Surjit, M.; Ganti, K.P.; Mukherji, A.; Ye, T.; Hua, G.; Metzger, D.; Li, M.; Chambon, P. Widespread Negative Response Elements
Mediate Direct Repression by Agonist- Liganded Glucocorticoid Receptor. Cell 2011, 145, 224–241. [CrossRef] [PubMed]
157. Ramamoorthy, S.; Cidlowski, J.A. Exploring the Molecular Mechanisms of Glucocorticoid Receptor Action from Sensitivity to
Resistance. Endocr. Dev. 2013, 24, 41–56. [CrossRef]
158. Escoter-Torres, L.; Caratti, G.; Mechtidou, A.; Tuckermann, J.; Uhlenhaut, N.H.; Vettorazzi, S. Fighting the Fire: Mechanisms of
Inflammatory Gene Regulation by the Glucocorticoid Receptor. Front. Immunol. 2019, 10, 1859. [CrossRef]
159. Oh, K.-S.; Patel, H.; Gottschalk, R.A.; Lee, W.S.; Baek, S.; Fraser, I.; Hager, G.L.; Sung, M.-H. Anti-Inflammatory Chromatinscape
Suggests Alternative Mechanisms of Glucocorticoid Receptor Action. Immunity 2017, 47, 298–309.e5. [CrossRef]
160. Ratman, D.; Berghe, W.V.; Dejager, L.; Libert, C.; Tavernier, J.; Beck, I.; De Bosscher, K. How glucocorticoid receptors modulate the
activity of other transcription factors: A scope beyond tethering. Mol. Cell. Endocrinol. 2013, 380, 41–54. [CrossRef]
161. Baudrand, R.; Pojoga, L.; Romero, J.R. Chapter 10—Aldosterone’s Mechanism of Action: Genomic and Nongenomic Signaling.
In Textbook of Nephro-Endocrinology, 2nd ed.; Singh, A.K., Williams, G.H., Eds.; Academic Press: Cambridge, MA, USA, 2018;
pp. 173–188. [CrossRef]
162. Reul, J.M.H.M.; de Kloet, R. Two Receptor Systems for Corticosterone in Rat Brain: Microdistribution and Differential Occupation.
Endocrinology 1985, 117, 2505–2511. [CrossRef]
163. Reul, J.M.; Collins, A.; Saliba, R.S.; Mifsud, K.; Carter, S.D.; Gutierrez-Mecinas, M.; Qian, X.; Linthorst, A.C. Glucocorticoids,
epigenetic control and stress resilience. Neurobiol. Stress 2014, 1, 44–59. [CrossRef]
164. Grossmann, C.; Gekle, M. Non-classical actions of the mineralocorticoid receptor: Misuse of EGF receptors? Mol. Cell. Endocrinol.
2007, 277, 6–12. [CrossRef] [PubMed]
165. Sireeni, J.; Bakker, N.; Jaikumar, G.; Obdam, D.; Slabbekoorn, H.; Tudorache, C.; Schaaf, M. Profound effects of glucocorticoid
resistance on anxiety-related behavior in zebrafish adults but not in larvae. Gen. Comp. Endocrinol. 2020, 292, 113461. [CrossRef]
166. Müller, M.B.; Holsboer, F.; Keck, M.E. Genetic modification of corticosteroid receptor signalling: Novel insights into pathophysiol-
ogy and treatment strategies of human affective disorders. Neuropeptides 2002, 36, 117–131. [CrossRef]
167. Van Eekelen, J.; Bohn, M.; De Kloet, E. Postnatal ontogeny of mineralocorticoid and glucocorticoid receptor gene expression in
regions of the rat tel- and diencephalon. Dev. Brain Res. 1991, 61, 33–43. [CrossRef]
168. Hartmann, J.; Bajaj, T.; Klengel, C.; Chatzinakos, C.; Ebert, T.; Dedic, N.; McCullough, K.M.; Lardenoije, R.; Joëls, M.; Meijer, O.C.;
et al. Mineralocorticoid receptors dampen glucocorticoid receptor sensitivity to stress via regulation of FKBP5. Cell Rep. 2021,
35, 109185. [CrossRef]
169. De Kloet, E.; Meijer, O.; de Nicola, A.; de Rijk, R.; Joëls, M. Importance of the brain corticosteroid receptor balance in metaplasticity,
cognitive performance and neuro-inflammation. Front. Neuroendocrinol. 2018, 49, 124–145. [CrossRef]
170. Lee, H.B.; Schwab, T.L.; Sigafoos, A.N.; Gauerke, J.L.; Ii, R.G.K.; Serres, M.R.; Jacobs, D.C.; Cotter, R.P.; Das, B.; Petersen, M.O.;
et al. Novel zebrafish behavioral assay to identify modifiers of the rapid, nongenomic stress response. Genes Brain Behav. 2018,
18, e12549. [CrossRef]
171. Marchi, D.; Santhakumar, K.; Markham, E.; Li, N.; Storbeck, K.-H.; Krone, N.; Cunliffe, V.T.; van Eeden, F.J.M. Bidirectional
crosstalk between Hypoxia-Inducible Factor and glucocorticoid signalling in zebrafish larvae. PLoS Genet. 2020, 16, e1008757.
[CrossRef]
172. Ince, L.M.; Weber, J.; Scheiermann, C. Control of Leukocyte Trafficking by Stress-Associated Hormones. Front. Immunol. 2019,
9, 3143. [CrossRef]
173. Coutinho, A.E.; Chapman, K.E. The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments
and mechanistic insights. Mol. Cell. Endocrinol. 2011, 335, 2–13. [CrossRef]
174. Schmidt, S.; Rainer, J.; Ploner, C.; Presul, E.; Riml, S.; Kofler, R. Glucocorticoid-induced apoptosis and glucocorticoid resistance:
Molecular mechanisms and clinical relevance. Cell Death Differ. 2004, 11, S45–S55. [CrossRef]
175. Planey, S.L.; Litwack, G. Glucocorticoid-Induced Apoptosis in Lymphocytes. Biochem. Biophys. Res. Commun. 2000, 279, 307–312.
[CrossRef]
Cells 2021, 10, 3441 24 of 27
176. Ashwell, J.D.; Lu, F.W.M.; Vacchio, M.S. Glucocorticoids in T Cell Development and Function. Annu. Rev. Immunol. 2000,
18, 309–345. [CrossRef]
177. Herold, M.J.; McPherson, K.G.; Reichardt, H.M. Glucocorticoids in T cell apoptosis and function. Cell. Mol. Life Sci. 2005, 63, 60–72.
[CrossRef] [PubMed]
178. McColl, A.; Bournazos, S.; Franz, S.; Perretti, M.; Morgan, B.P.; Haslett, C.; Dransfield, I. Glucocorticoids Induce Protein S-
Dependent Phagocytosis of Apoptotic Neutrophils by Human Macrophages. J. Immunol. 2009, 183, 2167–2175. [CrossRef]
[PubMed]
179. Miller, A.H.; Spencer, R.L.; Stein, M.; McEwen, B.S. Adrenal steroid receptor binding in spleen and thymus after stress or
dexamethasone. Am. J. Physiol. Metab. 1990, 259, E405. [CrossRef] [PubMed]
180. Barish, G.D.; Downes, M.; Alaynick, W.A.; Yu, R.T.; Ocampo, C.B.; Bookout, A.L.; Mangelsdorf, D.J.; Evans, R.M. A Nuclear
Receptor Atlas: Macrophage Activation. Mol. Endocrinol. 2005, 19, 2466–2477. [CrossRef]
181. Lim, H.-Y.; Müller, N.; Herold, M.J.; Brandt, J.V.D.; Reichardt, H.M. Glucocorticoids exert opposing effects on macrophage
function dependent on their concentration. Immunology 2007, 122, 47–53. [CrossRef]
182. Harizi, H.; Mormede, P.; Corcuff, J. Inter-strain differences in glucocorticoid and mineralocorticoid effects on macrophage and
lymphocyte functions in mice. J. Neuroimmunol. 2008, 204, 38–42. [CrossRef]
183. Bene, N.C.; Alcaide, P.; Wortis, H.H.; Jaffe, I.Z. Mineralocorticoid receptors in immune cells: Emerging role in cardiovascular
disease. Steroids 2014, 91, 38–45. [CrossRef]
184. Muñoz-Durango, N.; Vecchiola, A.; Gonzalez-Gomez, L.M.; Simon, F.; Riedel, C.; Fardella, C.E.; Kalergis, A.M. Modulation of
Immunity and Inflammation by the Mineralocorticoid Receptor and Aldosterone. BioMed Res. Int. 2015, 2015, 652738. [CrossRef]
185. Van Der Heijden, C.D.C.C.; Deinum, J.; Joosten, L.A.B.; Netea, M.G.; Riksen, N.P. The mineralocorticoid receptor as a modulator
of innate immunity and atherosclerosis. Cardiovasc. Res. 2018, 114, 944–953. [CrossRef]
186. Vandevyver, S.; Dejager, L.; Libert, C. On the Trail of the Glucocorticoid Receptor: Into the Nucleus and Back. Traffic 2011,
13, 364–374. [CrossRef]
187. Ronchetti, S.; Migliorati, G.; Riccardi, C. GILZ as a Mediator of the Anti-Inflammatory Effects of Glucocorticoids. Front. Endocrinol.
2015, 6, 170. [CrossRef]
188. Scheinman, R.I.; Gualberto, A.; Jewell, C.M.; Cidlowski, J.A.; Baldwin, A.S. Characterization of mechanisms involved in
transrepression of NF-kappa B by activated glucocorticoid receptors. Mol. Cell. Biol. 1995, 15, 943–953. [CrossRef]
189. Escoter-Torres, L.; Greulich, F.; Quagliarini, F.; Wierer, M.; Uhlenhaut, N.H. Anti-inflammatory functions of the glucocorticoid
receptor require DNA binding. Nucleic Acids Res. 2020, 48, 8393–8407. [CrossRef]
190. Stellato, C. Post-transcriptional and Nongenomic Effects of Glucocorticoids. Proc. Am. Thorac. Soc. 2004, 1, 255–263. [CrossRef]
191. De Bosscher, K.; Van Craenenbroeck, K.; Meijer, O.C.; Haegeman, G. Selective transrepression versus transactivation mechanisms
by glucocorticoid receptor modulators in stress and immune systems. Eur. J. Pharmacol. 2008, 583, 290–302. [CrossRef] [PubMed]
192. De Bosscher, K.; Haegeman, G.; Elewaut, D. Targeting inflammation using selective glucocorticoid receptor modulators. Curr.
Opin. Pharmacol. 2010, 10, 497–504. [CrossRef]
193. Davies, T.H.; Ning, Y.-M.; Sánchez, E.R. Differential Control of Glucocorticoid Receptor Hormone-Binding Function by Tetratri-
copeptide Repeat (TPR) Proteins and the Immunosuppressive Ligand FK506. Biochemistry 2005, 44, 2030–2038. [CrossRef]
194. Liberman, A.C.; Druker, J.; Perone, M.J.; Arzt, E. Glucocorticoids in the regulation of transcription factors that control cytokine
synthesis. Cytokine Growth Factor Rev. 2007, 18, 45–56. [CrossRef]
195. Pascual, G.; Glass, C.K. Nuclear receptors versus inflammation: Mechanisms of transrepression. Trends Endocrinol. Metab. 2006,
17, 321–327. [CrossRef] [PubMed]
196. Limbourg, F.P.; Liao, J.K. Nontranscriptional actions of the glucocorticoid receptor. J. Mol. Med. 2003, 81, 168–174. [CrossRef]
197. Liberman, A.C.; Refojo, D.; Druker, J.; Toscano, M.; Rein, T.; Holsboer, F.; Arzt, E. The activated glucocorticoid receptor inhibits
the transcription factor T-bet by direct protein-protein interaction. FASEB J. 2007, 21, 1177–1188. [CrossRef]
198. Vayssière, B.M.; Dupont, S.; Choquart, A.; Petit, F.; Garcia, T.; Marchandeau, C.; Gronemeyer, H.; Resche-Rigon, M. Synthetic
Glucocorticoids That Dissociate Transactivation and AP-1 Transrepression Exhibit Antiinflammatory Activity in Vivo. Mol.
Endocrinol. 1997, 11, 1245–1255. [CrossRef]
199. Belvisi, M.G.; Wicks, S.L.; Battram, C.H.; Bottoms, S.E.W.; Redford, J.E.; Woodman, P.; Brown, T.J.; Webber, S.E.; Foster,
M.L. Therapeutic Benefit of a Dissociated Glucocorticoid and the Relevance of In Vitro Separation of Transrepression from
Transactivation Activity. J. Immunol. 2001, 166, 1975–1982. [CrossRef]
200. Schacke, H.; Schottelius, A.; Docke, W.-D.; Strehlke, P.; Jaroch, S.; Schmees, N.; Rehwinkel, H.; Hennekes, H.; Asadullah,
K. Dissociation of transactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of
therapeutic effects from side effects. Proc. Natl. Acad. Sci. USA 2003, 101, 227–232. [CrossRef]
201. De Bosscher, K.; Beck, I.M.; Dejager, L.; Bougarne, N.; Gaigneaux, A.; Chateauvieux, S.; Ratman, D.; Bracke, M.; Tavernier, J.;
Berghe, W.V.; et al. Selective modulation of the glucocorticoid receptor can distinguish between transrepression of NF-κB and
AP-1. Cell. Mol. Life Sci. 2013, 71, 143–163. [CrossRef]
202. De Bosscher, K.; Berghe, W.V.; Beck, I.; Van Molle, W.; Hennuyer, N.; Hapgood, J.; Libert, C.; Staels, B.; Louw, A.; Haegeman, G. A
fully dissociated compound of plant origin for inflammatory gene repression. Proc. Natl. Acad. Sci. USA 2005, 102, 15827–15832.
[CrossRef]
Cells 2021, 10, 3441 25 of 27
203. Duque, E.D.A.; Munhoz, C.D. The Pro-inflammatory Effects of Glucocorticoids in the Brain. Front. Endocrinol. 2016, 7, 78.
[CrossRef]
204. Langlais, D.; Couture, C.; Balsalobre, A.; Drouin, J. Regulatory Network Analyses Reveal Genome-Wide Potentiation of LIF
Signaling by Glucocorticoids and Define an Innate Cell Defense Response. PLoS Genet. 2008, 4, e1000224. [CrossRef]
205. Langlais, D.; Couture, C.; Balsalobre, A.; Drouin, J. The Stat3/GR Interaction Code: Predictive Value of Direct/Indirect DNA
Recruitment for Transcription Outcome. Mol. Cell 2012, 47, 38–49. [CrossRef]
206. Dittrich, A.; Khouri, C.; Sackett, S.D.; Ehlting, C.; Böhmer, O.; Albrecht, U.; Bode, J.G.; Trautwein, C.; Schaper, F. Glucocorticoids
increase interleukin-6-dependent gene induction by interfering with the expression of the suppressor of cytokine signaling 3
feedback inhibitor. Hepatology 2011, 55, 256–266. [CrossRef]
207. Xie, Y.; Tolmeijer, S.; Oskam, J.M.; Tonkens, T.; Meijer, A.H.; Schaaf, M.J.M. Glucocorticoids inhibit macrophage differentiation
towards a pro-inflammatory phenotype upon wounding without affecting their migration. Dis. Model. Mech. 2019, 12. [CrossRef]
[PubMed]
208. Bos, R.V.D.; Cromwijk, S.; Tschigg, K.; Althuizen, J.; Zethof, J.; Whelan, R.; Flik, G.; Schaaf, M. Early Life Glucocorticoid Exposure
Modulates Immune Function in Zebrafish (Danio rerio) Larvae. Front. Immunol. 2020, 11, 727. [CrossRef] [PubMed]
209. John, S.; Sabo, P.J.; Thurman, R.E.; Sung, M.-H.; Biddie, S.; Johnson, T.A.; Hager, G.L.; Stamatoyannopoulos, J.A. Chromatin
accessibility pre-determines glucocorticoid receptor binding patterns. Nat. Genet. 2011, 43, 264–268. [CrossRef]
210. John, S.; Sabo, P.J.; Johnson, T.A.; Sung, M.-H.; Biddie, S.C.; Lightman, S.L.; Voss, T.C.; Davis, S.R.; Meltzer, P.S.; Stamatoy-
annopoulos, J.A.; et al. Interaction of the Glucocorticoid Receptor with the Chromatin Landscape. Mol. Cell 2008, 29, 611–624.
[CrossRef]
211. Ito, K.; Barnes, P.J.; Adcock, I.M. Glucocorticoid Receptor Recruitment of Histone Deacetylase 2 Inhibits Interleukin-1β-Induced
Histone H4 Acetylation on Lysines 8 and 12. Mol. Cell. Biol. 2000, 20, 6891–6903. [CrossRef]
212. Semenza, G.L. Hypoxia. Cross talk between oxygen sensing and the cell cycle machinery. Am. J. Physiol. Physiol. 2011,
301, C550–C552. [CrossRef]
213. Semenza, G.L. HIF-1 and mechanisms of hypoxia sensing. Curr. Opin. Cell Biol. 2001, 13, 167–171. [CrossRef]
214. Webb, J.D.; Coleman, M.L.; Pugh, C.W. Hypoxia, hypoxia-inducible factors (HIF), HIF hydroxylases and oxygen sensing. Cell.
Mol. Life Sci. 2009, 66, 3539. [CrossRef]
215. Pollenz, R.S.; Sattler, C.A.; Poland, A. The aryl hydrocarbon receptor and aryl hydrocarbon receptor nuclear translocator protein
show distinct subcellular localizations in Hepa 1c1c7 cells by immunofluorescence microscopy. Mol. Pharmacol. 1994, 45, 428–438.
[PubMed]
216. Eguchi, H.; Ikuta, T.; Tachibana, T.; Yoneda, Y.; Kawajiri, K. A Nuclear Localization Signal of Human Aryl Hydrocarbon Receptor
Nuclear Translocator/Hypoxia-inducible Factor 1β Is a Novel Bipartite Type Recognized by the Two Components of Nuclear
Pore-targeting Complex. J. Biol. Chem. 1997, 272, 17640–17647. [CrossRef]
217. Iwai, K.; Yamanaka, K.; Kamura, T.; Minato, N.; Conaway, R.C.; Conaway, J.; Klausner, R.D.; Pause, A. Identification of the
von Hippel-Lindau tumor-suppressor protein as part of an active E3 ubiquitin ligase complex. Proc. Natl. Acad. Sci. USA 1999,
96, 12436–12441. [CrossRef]
218. Shay, J.E.; Simon, M.C. Hypoxia-inducible factors: Crosstalk between inflammation and metabolism. Semin. Cell Dev. Biol. 2012,
23, 389–394. [CrossRef]
219. Siddiq, A.; Aminova, L.R.; Ratan, R.R. Hypoxia Inducible Factor Prolyl 4-Hydroxylase Enzymes: Center Stage in the Battle
Against Hypoxia, Metabolic Compromise and Oxidative Stress. Neurochem. Res. 2007, 32, 931–946. [CrossRef]
220. Pan, Y.; Mansfield, K.D.; Bertozzi, C.C.; Rudenko, V.; Chan, D.A.; Giaccia, A.J.; Simon, M.C. Multiple Factors Affecting Cellular
Redox Status and Energy Metabolism Modulate Hypoxia-Inducible Factor Prolyl Hydroxylase Activity In Vivo and In Vitro. Mol.
Cell. Biol. 2007, 27, 912–925. [CrossRef] [PubMed]
221. Masson, N.; Singleton, R.S.; Sekirnik, R.; Trudgian, D.C.; Ambrose, L.J.; Miranda, M.X.; Tian, Y.; Kessler, B.M.; Schofield, C.J.;
Ratcliffe, P.J. The FIH hydroxylase is a cellular peroxide sensor that modulates HIF transcriptional activity. EMBO Rep. 2012,
13, 251–257. [CrossRef]
222. Rhee, S.G.; Woo, H.A.; Kil, I.S.; Bae, S.H. Peroxiredoxin Functions as a Peroxidase and a Regulator and Sensor of Local Peroxides.
J. Biol. Chem. 2012, 287, 4403–4410. [CrossRef]
223. Palazon, A.; Goldrath, A.W.; Nizet, V.; Johnson, R.S. HIF Transcription Factors, Inflammation, and Immunity. Immunity 2014,
41, 518–528. [CrossRef]
224. Semenza, G.L. Oxygen Sensing, Homeostasis, and Disease. N. Engl. J. Med. 2011, 365, 537–547. [CrossRef]
225. Safronova, O.; Morita, I. Transcriptome Remodeling in Hypoxic Inflammation. J. Dent. Res. 2010, 89, 430–444. [CrossRef]
226. Bosco, M.C.; Puppo, M.; Blengio, F.; Fraone, T.; Cappello, P.; Giovarelli, M.; Varesio, L. Monocytes and dendritic cells in a hypoxic
environment: Spotlights on chemotaxis and migration. Immunobiology 2008, 213, 733–749. [CrossRef] [PubMed]
227. Murdoch, C.; Muthana, M.; Lewis, C.E. Hypoxia Regulates Macrophage Functions in Inflammation. J. Immunol. 2005,
175, 6257–6263. [CrossRef] [PubMed]
228. Lewis, C.; Murdoch, C. Macrophage Responses to Hypoxia: Implications for Tumor Progression and Anti-Cancer Therapies. Am.
J. Pathol. 2005, 167, 627–635. [CrossRef]
229. Safronova, O.; Pluemsampant, S.; Nakahama, K.-I.; Morita, I. Regulation of chemokine gene expression by hypoxia via cooperative
activation of NF-κB and histone deacetylase. Int. J. Biochem. Cell Biol. 2009, 41, 2270–2280. [CrossRef]
Cells 2021, 10, 3441 26 of 27
230. Yamamoto, Y.; Yin, M.-J.; Gaynor, R.B. IκB Kinase α (IKKα) Regulation of IKKβ Kinase Activity. Mol. Cell. Biol. 2000, 20, 3655–3666.
[CrossRef]
231. Cummins, E.P.; Berra, E.; Comerford, K.M.; Ginouves, A.; Fitzgerald, K.T.; Seeballuck, F.; Godson, C.; Nielsen, J.E.; Moynagh, P.;
Pouyssegur, J.; et al. Prolyl hydroxylase-1 negatively regulates IκB kinase-β, giving insight into hypoxia-induced NFκB activity.
Proc. Natl. Acad. Sci. USA 2006, 103, 18154–18159. [CrossRef]
232. Cummins, E.; Comerford, K.M.; Scholz, C.; Bruning, U.; Taylor, C. Hypoxic Regulation of NF-κB Signaling. Methods Enzymol.
2007, 435, 479–492. [CrossRef]
233. van Uden, P.; Kenneth, N.S.; Rocha, S. Regulation of hypoxia-inducible factor-1α by NF-κB. Biochem. J. 2008, 412, 477–484.
[CrossRef]
234. van Uden, P.; Kenneth, N.S.; Webster, R.; Müller, H.A.; Mudie, S.; Rocha, S. Evolutionary Conserved Regulation of HIF-1β by
NF-κB. PLoS Genet. 2011, 7, e1001285. [CrossRef]
235. Rius, J.; Guma, M.; Schachtrup, C.; Akassoglou, K.; Zinkernagel, A.S.; Nizet, V.; Johnson, R.S.; Haddad, G.G.; Karin, M. NF-κB
links innate immunity to the hypoxic response through transcriptional regulation of HIF-1α. Nature 2008, 453, 807–811. [CrossRef]
[PubMed]
236. D’Ignazio, L.; Bandarra, D.; Rocha, S. NF-κB and HIF crosstalk in immune responses. FEBS J. 2015, 283, 413–424. [CrossRef]
[PubMed]
237. Schild, Y.; Mohamed, A.; Wootton, E.J.; Lewis, A.; Elks, P.M. Hif-1alpha stabilisation is protective against infection in zebrafish
comorbid models. FEBS J. 2020, 287, 3925–3943. [CrossRef] [PubMed]
238. Charron, C.E.; Chou, P.-C.; Coutts, D.J.C.; Kumar, V.; To, M.; Akashi, K.; Pinhu, L.; Griffiths, M.; Adcock, I.; Barnes, P.J.;
et al. Hypoxia-inducible Factor 1α Induces Corticosteroid-insensitive Inflammation via Reduction of Histone Deacetylase-2
Transcription. J. Biol. Chem. 2009, 284, 36047–36054. [CrossRef]
239. Huang, Y.; Zhao, J.-J.; Lv, Y.-Y.; Ding, P.-S.; Liu, R.-Y. Hypoxia down-regulates glucocorticoid receptor alpha and attenuates the
anti-inflammatory actions of dexamethasone in human alveolar epithelial A549 cells. Life Sci. 2009, 85, 107–112. [CrossRef]
[PubMed]
240. Vanderhaeghen, T.; Timmermans, S.; Watts, D.; Paakinaho, V.; Eggermont, M.; Vandewalle, J.; Wallaeys, C.; Van Wyngene, L.;
Van Looveren, K.; Nuyttens, L.; et al. Reprogramming of glucocorticoid receptor function by hypoxia. EMBO Rep. 2021, e53083.
[CrossRef] [PubMed]
241. Elsby, L.M.; Donn, R.; Alourfi, Z.; Green, L.M.; Beaulieu, E.; Ray, D.W. Hypoxia and glucocorticoid signaling converge to regulate
macrophage migration inhibitory factor gene expression. Arthritis Rheum. 2009, 60, 2220–2231. [CrossRef] [PubMed]
242. Wang, Y.; Ma, Y.-Y.; Song, X.-L.; Cai, H.-Y.; Chen, J.-C.; Song, L.-N.; Yang, R.; Lu, J. Upregulations of Glucocorticoid-Induced
Leucine Zipper by Hypoxia and Glucocorticoid Inhibit Proinflammatory Cytokines under Hypoxic Conditions in Macrophages.
J. Immunol. 2011, 188, 222–229. [CrossRef]
243. Ayroldi, E.; Riccardi, C. Glucocorticoid-induced leucine zipper (GILZ): A new important mediator of glucocorticoid action.
FASEB J. 2009, 23, 3649–3658. [CrossRef]
244. Cannarile, L.; Delfino, D.V.; Adorisio, S.; Riccardi, C.; Ayroldi, E. Implicating the Role of GILZ in Glucocorticoid Modulation of
T-Cell Activation. Front. Immunol. 2019, 10, 1823. [CrossRef] [PubMed]
245. Lee, C.-H.; Choi, E.Y. Macrophages and Inflammation. J. Rheum. Dis. 2018, 25, 11–18. [CrossRef]
246. Xue, L.; Greisler, H.P. Angiogenic effect of fibroblast growth factor-1 and vascular endothelial growth factor and their synergism
in a novel in vitro quantitative fibrin-based 3-dimensional angiogenesis system. Surgery 2002, 132, 259–267. [CrossRef]
247. Ke, X.; Chen, C.; Song, Y.; Cai, Q.; Li, J.; Tang, Y.; Han, X.; Qu, W.; Chen, A.; Wang, H.; et al. Hypoxia modifies the polarization
of macrophages and their inflammatory microenvironment, and inhibits malignant behavior in cancer cells. Oncol. Lett. 2019,
18, 5871–5878. [CrossRef] [PubMed]
248. Liu, B.; Goodwin, J.E. The Effect of Glucocorticoids on Angiogenesis in the Treatment of Solid Tumors. J. Cell. Signal. 2020,
1, 42–49. [CrossRef]
249. Bernhardt, W.M.; Câmpean, V.; Kany, S.; Jürgensen, J.-S.; Weidemann, A.; Warnecke, C.; Arend, M.; Klaus, S.; Günzler, V.; Amann,
K.; et al. Preconditional Activation of Hypoxia-Inducible Factors Ameliorates Ischemic Acute Renal Failure. J. Am. Soc. Nephrol.
2006, 17, 1970–1978. [CrossRef]
250. Wan, C.; Gilbert, S.R.; Wang, Y.; Cao, X.; Shen, X.; Ramaswamy, G.; Jacobsen, K.A.; Alaql, Z.S.; Eberhardt, A.W.; Gerstenfeld,
L.C.; et al. Activation of the hypoxia-inducible factor-1 pathway accelerates bone regeneration. Proc. Natl. Acad. Sci. USA 2008,
105, 686–691. [CrossRef]
251. Semenza, G.L. Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer 2003, 3, 721–732. [CrossRef]
252. Semenza, G.L. HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations. J. Clin. Investig. 2013,
123, 3664–3671. [CrossRef]
253. Vettori, A.; Greenald, D.; Wilson, G.K.; Peron, M.; Facchinello, N.; Markham, E.; Sinnakaruppan, M.; Matthews, L.C.; McKeating,
J.A.; Argenton, F.; et al. Glucocorticoids promote Von Hippel Lindau degradation and Hif-1α stabilization. Proc. Natl. Acad. Sci.
USA 2017, 114, 9948–9953. [CrossRef]
254. Wright, A.D.; Brearey, S.P.; Imray, C.H.E. High hopes at high altitudes: Pharmacotherapy for acute mountain sickness and
high-altitude cerebral and pulmonary oedema. Expert Opin. Pharmacother. 2007, 9, 119–127. [CrossRef]
Cells 2021, 10, 3441 27 of 27
255. Dardzinski, B.J.; Smith, S.L.; Towfighi, J.; Williams, G.D.; Vannucci, R.C.; Smith, M.B. Increased Plasma Beta-Hydroxybutyrate, Pre-
served Cerebral Energy Metabolism, and Amelioration of Brain Damage During Neonatal Hypoxia Ischemia with Dexamethasone
Pretreatment. Pediatr. Res. 2000, 48, 248–255. [CrossRef]
256. Limbourg, F.P.; Huang, Z.; Plumier, J.-C.; Simoncini, T.; Fujioka, M.; Tuckermann, J.; Schutz, G.; Moskowitz, M.A.; Liao, J.K. Rapid
nontranscriptional activation of endothelial nitric oxide synthase mediates increased cerebral blood flow and stroke protection by
corticosteroids. J. Clin. Investig. 2002, 110, 1729–1738. [CrossRef]
257. Glanemann, M.; Strenziok, R.; Kuntze, R.; Münchow, S.; Dikopoulos, N.; Lippek, F.; Langrehr, J.M.; Dietel, M.; Neuhaus, P.;
Nussler, A.K. Ischemic preconditioning and methylprednisolone both equally reduce hepatic ischemia/reperfusion injury. Surgery
2004, 135, 203–214. [CrossRef]
258. Tokudome, S.; Sano, M.; Shinmura, K.; Matsuhashi, T.; Morizane, S.; Moriyama, H.; Tamaki, K.; Hayashida, K.; Nakanishi,
H.; Yoshikawa, N.; et al. Glucocorticoid protects rodent hearts from ischemia / reperfusion injury by activating lipocalin-type
prostaglandin D synthase—Derived PGD 2 biosynthesis. J. Clin. Investig. 2009, 119, 1477–1488. [CrossRef] [PubMed]
259. Zhang, C.; Qiang, Q.; Jiang, Y.; Hu, L.; Ding, X.; Lu, Y.; Hu, G. Effects of hypoxia inducible factor-1α on apoptotic inhibition and
glucocorticoid receptor downregulation by dexamethasone in AtT-20 cells. BMC Endocr. Disord. 2015, 15, 24. [CrossRef]
260. Gaber, T.; Schellmann, S.; Erekul, K.B.; Fangradt, M.; Tykwinska, K.; Hahne, M.; Maschmeyer, P.; Wagegg, M.; Stahn, C.; Kolar, P.;
et al. Macrophage Migration Inhibitory Factor Counterregulates Dexamethasone-Mediated Suppression of Hypoxia-Inducible
Factor-1α Function and Differentially Influences Human CD4+ T Cell Proliferation under Hypoxia. J. Immunol. 2010, 186, 764–774.
[CrossRef]
261. Wu, R.S.; Lam, I.I.; Clay, H.; Duong, D.N.; Deo, R.C.; Coughlin, S.R. A Rapid Method for Directed Gene Knockout for Screening
in G0 Zebrafish. Dev. Cell 2018, 46, 112–125. [CrossRef] [PubMed]
262. Burger, A.; Lindsay, H.; Felker, A.; Hess, C.; Anders, C.; Chiavacci, E.; Zaugg, J.; Weber, L.M.; Catena, R.; Jinek, M.; et al.
Maximizing mutagenesis with solubilized CRISPR-Cas9 ribonucleoprotein complexes. Development 2016, 143, 2025–2037.
[CrossRef]
263. Wilkinson, L.; Verhoog, N.; Louw, A. Novel role for receptor dimerization in post-translational processing and turnover of the
GRα. Sci. Rep. 2018, 8, 14266. [CrossRef]
264. Pace, T.W.; Hu, F.; Miller, A.H. Cytokine-effects on glucocorticoid receptor function: Relevance to glucocorticoid resistance and
the pathophysiology and treatment of major depression. Brain Behav. Immun. 2007, 21, 9–19. [CrossRef]
265. Tan, T.; Yu, R.M.K.; Wu, R.S.S.; Kong, R.Y.C. Overexpression and Knockdown of Hypoxia-Inducible Factor 1 Disrupt the
Expression of Steroidogenic Enzyme Genes and Early Embryonic Development in Zebrafish. Gene Regul. Syst. Biol. 2017, 11.
[CrossRef]
266. Egg, M.; Köblitz, L.; Hirayama, J.; Schwerte, T.; Folterbauer, C.; Kurz, A.; Fiechtner, B.; Möst, M.; Salvenmoser, W.; Sassone-Corsi,
P.; et al. Linking Oxygen to Time: The Bidirectional Interaction Between the Hypoxic Signaling Pathway and the Circadian Clock.
Chronobiol. Int. 2013, 30, 510–529. [CrossRef] [PubMed]
267. Egg, M.; Paulitsch, M.; Ennemoser, Y.; Wüstenhagen, A.; Schwerte, T.; Sandbichler, A.M.; Fiechtner, B.; Köblitz, L.; Prem, C.;
Pelster, B. Chronodisruption increases cardiovascular risk in zebrafish via reduced clearance of senescent erythrocytes. Chronobiol.
Int. 2014, 31, 680–689. [CrossRef] [PubMed]
268. Pelster, B.; Egg, M. Multiplicity of Hypoxia-Inducible Transcription Factors and Their Connection to the Circadian Clock in the
Zebrafish. Physiol. Biochem. Zool. 2015, 88, 146–157. [CrossRef] [PubMed]
269. Peek, C.B.; Levine, D.; Cedernaes, J.; Taguchi, A.; Kobayashi, Y.; Tsai, S.J.; Bonar, N.A.; McNulty, M.R.; Ramsey, K.M.; Bass, J.
Circadian Clock Interaction with HIF1α Mediates Oxygenic Metabolism and Anaerobic Glycolysis in Skeletal Muscle. Cell Metab.
2016, 25, 86–92. [CrossRef] [PubMed]
270. Yang, N.; Berry, A.; Sauer, C.; Baxter, M.; Donaldson, I.J.; Forbes, K.; Donn, R.; Matthews, L.; Ray, D. Hypoxia regulates GR
function through multiple mechanisms involving microRNAs 103 and 107. Mol. Cell. Endocrinol. 2020, 518, 111007. [CrossRef]
271. Watts, D.; Stein, J.; Meneses, A.; Bechmann, N.; Neuwirth, A.; Kaden, D.; Krüger, A.; Sinha, A.; Alexaki, V.I.; Perez-Rivas, L.G.;
et al. HIF1α is a direct regulator of steroidogenesis in the adrenal gland. Cell. Mol. Life Sci. 2021, 78, 3577–3590. [CrossRef]
[PubMed]
272. Rybnikova, E.; Glushchenko, T.; Churilova, A.; Pivina, S.; Samoilov, M. Expression of glucocorticoid and mineralocorticoid
receptors in hippocampus of rats exposed to various modes of hypobaric hypoxia: Putative role in hypoxic preconditioning.
Brain Res. 2011, 1381, 66–77. [CrossRef]
273. Robinson, P.C.; Morand, E. Divergent effects of acute versus chronic glucocorticoids in COVID-19. Lancet Rheumatol. 2021,
3, e168–e170. [CrossRef]
274. van Paassen, J.; Vos, J.S.; Hoekstra, E.M.; Neumann, K.M.I.; Boot, P.C.; Arbous, S.M. Corticosteroid use in COVID-19 patients:
A systematic review and meta-analysis on clinical outcomes. Crit. Care 2020, 24, 696. [CrossRef] [PubMed]
